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Chapter 1
The kidneys and the arteries are subject to age-related alterations and can be 
affected by shared risk factors. In this thesis, consequences of age-related and 
risk factor related renovascular changes in late life are investigated.
 The kidneys are involved in many different essential processes in the 
human body. The kidneys work to maintain a constant extracellular environment 
that is required for adequate functioning of the cells. The nephrons, the 
functional unit of the kidneys, excrete waste products of metabolism and adjust 
urinary excretion of water and electrolytes in order to maintain homeostasis 
and regulate blood pressure. The glomerulus, the first part of the nephron, is 
the filtering unit with a three-layered structure that facilitates the flow of plasma 
water and small solutes and restricts the flow of large plasma proteins such 
as albumin. Kidney function is usually expressed as the glomerular filtration 
rate (GFR) and describes the total amount of fluid filtered per time unit. The 
second part of the nephron, the tubule, contains the fluid filtered through the 
glomerulus. By changes in tubular secretion and reabsorption, the kidneys 
are able to regulate the excretion of water and solutes such as electrolytes, 
organic acids, medications and toxins. The kidneys also have endocrine and 
metabolic functions; the kidneys produce hormones such as renin to help 
regulate blood pressure; erythropoietin, needed for the production of red blood 
cells, and activate vitamin D, which helps to maintain strong bones. During 
the aging process, all functions of the kidneys can be affected. In particular 
the number of nephrons decreases with 7.3% per age decade as result of 
sclerosis, atrophy and reabsorption.1,2 Age-related loss of kidney function can 
be accelerated by several risk factors such as diabetes mellitus, hypertension 
and metabolic syndrome leading to chronic kidney disease (CKD).3
  Measuring GFR is complex and time consuming in clinical practice and 
therefore GFR is estimated from serum markers.4 Most often, serum creatinine 
levels are used to estimate kidney function, a product from the metabolism 
of creatine in skeletal muscle.5 Creatinine production is therefore partly 
dependent on sex, age and body composition. Because of the lower muscle 
mass in women and older adults and the large variation in it,6 the accuracy of 
currently used kidney function estimations, especially at older age, should be 
seriously questioned. Several equations can be found in the literature, which 
all have in common that these are corrected for factors influencing muscle 
mass.5,7 However, the estimations show large variations in GFR, depending 
on which equation we use, with all consequences that this might entail.5 It 
is of paramount importance to accurately assess kidney function, since 
misclassification can have implications on treatment strategies, such as failing 
to redose renally cleared drugs which might result in under- or overdosing and 
risk of adverse drug reactions.8,9
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 CKD, defined as a GFR below 60 mL per minute for more than 3 months,4 is 
becoming more prevalent as result of the aging population and an increase in 
the number of risk factors of kidney function decline.3  The severity of CKD can 
be classified based on eGFR in 5 stages using the Kidney Disease Improving 
Global Outcomes (KDIGO) guidelines4: eGFR ≥ 90, stage 1; eGFR 60 - 89.9 
stage 2; eGFR 45 - 59.9, stage 3a; eGFR 30 - 44.9, stage 3b; eGFR 15 - 
29.9, stage 4 and eGFR <15 ml/min/1.73m², stage 5. It should be noted that 
persons with an eGFR <60 ml/min/1.73m² should not be classified as having 
CKD unless they have other markers of kidney disease such as albuminuria.4 
Both early and advanced stages of CKD are associated with an increased risk 
of end-stage renal disease, comorbidity and higher mortality.10,11 CKD also 
affects other outcomes relevant to older adults; decreased GFR is associated 
with lower physical function, joint problems and cognitive impairment and 
moreover, when kidney function declines, many drugs may accumulate 
which increases the risk of adverse drug reactions.9,12,13 This is especially 
relevant in older adults, a population with high prevalences of multimorbidity 
and therefore polypharmacy.14 Altogether, CKD has become a relevant public 
health care burden, which makes early detection of CKD relevant in order 
to identify and treat older adults with increased risk of adverse outcomes. 
However, an accurate method to screen for CKD, especially at older age, is 
still needed since data from younger populations cannot be extrapolated one 
on one to older adults.
 Closely linked to the age-related changes of the kidney is the 
process of age-related changes of the vascular system. The main function 
of the arteries is to adequately deliver oxygen and nutrients to every cell in 
the human body. For this purpose, the arteries transform the pulsatile flow 
that the heart rhythmically generates into a steady blood flow. This function 
depends on the viscoelastic properties of the central arteries, of which 
essential elements are collagen, elastin and smooth muscle cells. Vascular 
aging is characterized by breaks in elastin fibers, the stretchable element 
of the arterial wall, and an accumulation of collagen, the stress resistant 
element of the arterial wall, resulting in a decline of the elastic properties 
and thus an increase in arterial stiffness.15 The main determinant of arterial 
stiffness is age,16 however this process can, just as kidney function decline, 
be accelerated by several cardiovascular risk factors.17 
  Increased arterial stiffness influences and modifies blood pressure 
profiles; arterial stiffness can cause an impaired cardiovagal baroreflex 
sensitivity, which plays an important role in short term blood pressure 
regulation.18 Failure of this mechanism may lead to orthostatic hypotension, 
a common condition in older adults.19,20 Stiff arteries also result in higher 
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systolic pressure because of a reduced capacitance and a lower diastolic 
pressure because of a less elastic recoil to support the diastolic pressure.21 In 
addition, arterial stiffness increases the pulsatile pressure,21 which represents 
the variations of the pressure curve around the steady component; this 
increased pressure can affect the microcirculation of high-flow organs such 
as the brain, the heart, and the kidneys.22 As result of these hemodynamic 
changes, elevated arterial stiffness increases the risk of clinical and subclinical 
cardiovascular morbidity, such as the risk of stroke and myocardial infarction, 
and also the risk of mortality.22-24 There seems to be increasing evidence that 
link arterial stiffness to other (non-cardiovascular) age-related degenerative 
processes, such as bone demineralization, muscle loss and consequent 
decreased quality of life.25-27 However, it is not clear whether these processes 
share common pathways or even directly influence one another.
 Identifying adults with elevated arterial stiffness could help to monitor 
and treat modifiable risk factors which might help to prevent the development 
of adverse outcome. Therefore, it is very relevant to investigate the role of 
arterial stiffness in terms of physical and mental health in late life to better 
understand clinical implications and to be able to implement arterial stiffness 
in current guidelines of treating older adults. 
Part I of this thesis focusses on renal aging. The aim of this part of the 
thesis is to study clinical implications of using GFR equations at older age 
and to investigate the association of kidney function and geriatric outcome 
measures in late life. In chapter 2.1, we present the design of the SCOPE 
study, a multicenter cohort observational study on Screening for CKD 
among Older People across Europe. In chapter 3.1, the clinical implications 
of using GFR equations at older age are presented, based on preliminary 
results of the SCOPE study. In chapter 3.2, we investigate the possible 
relationship of estimated GFR and muscle mass and function in older adults 
of the IMPROveFALL study. Chapter 4 focusses on associations between 
kidney function, cognition and mood in late life, also based on results of the 
SCOPE study. Part II of the thesis focuses on vascular aging and the role of 
blood pressure. The aim of this part of the thesis is to study the link between 
vascular aging and physical and mental health in diverse study populations 
of older adults. In chapter 5.1, we outline possible hypotheses regarding 
associations between arterial stiffness, bone demineralization and muscle 
loss by reviewing previous literature. Chapter 5.2 investigates the possible 
impact of aortic stiffness on quality of late life, based on the Dutch study 
population of the SCOPE study. In chapter 5.3, we describe associations 
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between aortic stiffness and brain integrity in older adults with functional and 
cognitive complaints. In chapter 6.1, the role of orthostatic hypotension, 
as part of the process of vascular aging, is investigated in older fallers in 
order the examine the impact of blood pressure dysregulation on physical 
performance and fear of falling. Finally, in the general discussion in chapter 
7, the main findings of this thesis are discussed including clinical implications 
and future directions. In chapter 8 and 9 an English and Dutch summary 
are provided. The overall aim of the thesis is to better understand the role of 
renovascular aging in late life. 
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Screening for Chronic Kidney Disease
2.1 
Design and methodology of 
the Screening for CKD among 
Older People across Europe 
(SCOPE) study
A. Corsonello,  L. Tap, R. Roller-Wirnsberger, G. Wirnsberger, C. Zoccali, 
T. Kostka, A. Guligowska, F. Mattace-Raso, P. Gil, L. Guardado Fuentes, 
I. Melzer, I. Yehoshua, F. Formiga, R. Moreno-Gonzalez, C. Weingart, 
E. Freiberger, J. Ärnlöv, A. Carlsson, S. Bustacchini, F. Lattanzio 
on behalf of SCOPE investigators 
 
Design and methodology of the screening for CKD among older patients 
across Europe (SCOPE) study: a multicenter cohort observational study
BMC Nephrology, Oct. 2018
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Abstract
Background: Decline of renal function is common in older persons and the 
prevalence of chronic kidney disease (CKD) is rising with ageing. CKD affects 
different outcomes relevant to older persons, additionally to morbidity and 
mortality which makes CKD a relevant health burden in this population. Still, 
accurate laboratory measurement of kidney function is under debate, since 
current creatinine-based equations have a certain degree of inaccuracy 
when used in the older population. The aims of the study are as follows: 
to assess kidney function in a cohort of 75+ older persons using existing 
methodologies for CKD screening; to investigate existing and innovative 
biomarkers of CKD in this cohort, and to align laboratory and biomarker results 
with medical and functional data obtained from this cohort. The study was 
registered at ClinicalTrials.gov, identifier NCT02691546, February 25th 2016. 
 
Methods/design: An observational, multinational, multicenter, prospective 
cohort study in community dwelling persons aged 75 years and over, visiting 
the outpatient clinics of participating institutions. The study will enroll 2450 
participants and is carried out in Austria, Germany, Israel, Italy, the Netherlands, 
Poland and Spain. Participants will undergo clinical and laboratory evaluations 
at baseline and after 12 and 24 months- follow-up. Clinical evaluation also 
includes a comprehensive geriatric assessment (CGA). Local laboratory will 
be used for ‘basic’ parameters (including serum creatinine and albumin-to-
creatinine ratio), whereas biomarker assessment will be conducted centrally. 
An intermediate telephone follow-up will be carried out at 6 and 18 months. 
 
Discussion: Combining the use of CGA and the investigation of novel and 
existing independent biomarkers within the SCOPE study will help to provide 
evidence in the development of European guidelines and recommendations 
in the screening and management of CKD in older people.
23
2
Screening for Chronic Kidney Disease
Background
Evidence from epidemiological and clinical literature suggests that ageing 
contributes to the incidence of reduced renal filtration capacity.1 In the 
presence of risk factors during ageing, such as diabetes, hypertension and 
others, filtration capacity further declines. This concept is underlined by many 
epidemiological studies showing a decline of measured estimated glomerular 
filtration rate (eGFR) with advancing age.2 Kidney function is usually assessed 
by creatinine-based estimated glomerular filtration rate (eGFR) equations. 
However, those formulae have a certain degree of inaccuracy when used in 
older people due to changes in anthropometry and renal physiology during 
ageing.3 Alternative filtration markers yielded different eGFR values for different 
cohorts of people tested.4 This inaccuracy of laboratory measurements of 
kidney function suggests a risk of underdetection or overdetection of CKD, 
especially with advancing age.5 Indeed, the eGFR threshold at which the risk 
of negative outcomes increases among older patients is hotly debated,6 and 
current evidence suggests that such a threshold may be lower among older 
people compared to adult ones.7-9 Additionally, the eGFR cut-offs at which the 
risk of death starts to increase may change as a function of the equation used 
among older people.10 Thus, improving accuracy of CKD screening measures 
for older populations would be of help in reducing the risk of underdiagnosis 
to maximize prevention of CKD and its consequences while minimising the 
risks and cost of  overdiagnosis.6
  Diminished kidney function has become a relevant public health 
burden for all age groups, as CKD frequently results in an increased risk of 
end stage renal disease (ESRD), corbidity and mortality.11 Besides “traditional” 
endpoints, CKD has been shown to impact nutritional status, inflammatory 
processes and anemia, 12 thereby affecting different outcomes especially 
relevant to older people. These include impaired physical function, frailty 
and disability,13-16 cognitive impairment and dementia,17-19 depression,20-22 
sensory impairment,23 undernutrition and sarcopenia, 24-26 and adverse drug 
reactions (ADRs).27,28 Therefore, early and sensitive detection of diminished 
renal function is essential to individually address care needs of older people 
with CKD and to address one of the major health burden in public health for 
the incoming decades.29 
  Incorporating scoring risk models for care planning of older people 
at risk for CKD has come into focus recently.30 Risk prediction models are 
generally based on equations designed on the basis of prognostic factors and 
clinical outcomes, available at the time the prediction is made, and collected 
in specific and representative cohorts of individuals followed up for a given 
24
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period of time.31 Built on evidence of such models, screening programmes 
for CKD can take into account the characteristics of the target population 
in addition to simple laboratory measures, biomarkers and disease-based 
investigations. Multi- and co-morbidity, polypharmacy, frailty, functional and 
cognitive impairment and disability should be considered as part of a patient 
centered approach in CKD management especially in older adults.13,15,23-26,32-34
  So far, no CKD screening program has included all those variables 
also including data from comprehensive geriatric assessment (CGA), the only 
assessment technology able to capture the numerous domains of health 
status and their complex interactions in older people. Accordingly, the need 
for laboratory measurements able to identify accurately older people with CKD 
is a demand to address the public health challenges arising from the current 
demographic shifts. Indeed, this view is widely shared by the geriatric and 
nephrology communities, both in EU and USA.35,36
  The aims of this multicenter study in Europe are to assess existing 
methodologies for CKD screening and investigate existing and innovative 
biomarkers of CKD in older persons. Furthermore, the Screening for CKD 
among Older People across Europe (SCOPE) study will provide evidence for 
including physical and functional health parameters of older people across 
Europe and help design a tailored risk prediction model for CKD in old age. 
Methods
Study design
The SCOPE study is designed as an observational, multinational, multicenter, 
prospective cohort study in persons older than 75 years across Europe. This 
study is carried out in seven countries,  including Austria, Germany, Israel, 
Italy, the Netherlands, Poland and Spain. Participants will undergo clinical and 
laboratory evaluations at the baseline (recruitment), and will be followed up at 
face to face visits at months 12 and 24 following enrollment. An intermediate 
telephone follow-up will be carried out at 6 and 18 months following recruitment.
Figure 1 shows the schematic flow of the observational clinical study. 
 The study design complies with the Declaration of Helsinki and Good 
Clinical Practice Guidelines. The enrollment has started in August 2016 and is 
ongoing.  
25
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Figure 1. Study design of the SCOPE project
 
Ethical approval/ monitoring
The study protocol was approved by ethics committees at all participating 
institutions. Patients are requested to sign a written informed consent before 
entering the study. Patients are also asked to sign a separate informed 
consent to the collection of DNA samples to be used for genetic testing, 
while those not giving their consent will be retained in the main cohort study.
  In order to ensure high ethical and scientific standards of the project 
and to monitor the progress of the clinical study a Scientific Advisory Board 
(SAB) and a Data and Ethics Management Board (DEMB) was implemented 
within the Governance Structure. The SAB ensures a high standard of 
research, monitors the progress of the project by taking part in the project 
meetings, and provides final approval to any required study amendments. The 
DEMB supports the preparation of the relevant end-points for ethical review, 
advises on local research Ethical Committee applications, and reviews the 
relevant safety, morbidity and mortality end-points during the course of the 
study. The DEMB maintains an overview of the work throughout the whole 
course of the project and helps to foresee possible problems that might arise 
and how they can be addressed.
Study population
Persons aged 75 years and older, visiting the outpatient clinics of participating 
institutions are eligible for inclusion. The study design aims at minimizing self-
26
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selection bias and enrolling real-world patients without stringent inclusion/
exclusion criteria. The few exclusion criteria are outlined in Table 1. Therefore, 
no other inclusion criteria will be considered. The SCOPE study aims to finally 
enroll 2450 participants.
 
Table 1. Exclusion criteria for participants enrollment into the SCOPE project 
• Age < 75 years
• End stage renal disease (< 15 mL/min/1.73 m2) or dialysis at time of enrollment
• History of solid organ or bone marrow transplantation
• Active malignancy within 24 months prior to screening or metastatic cancer
• Life expectancy less than 6 months
• Severe cognitive impairment (Mini Mental State Examination < 10)
• Any medical or other reason (e.g. known or suspected inability of the patient to 
comply with the protocol procedure) in the judgement of the investigators, that the 
patient is unsuitable for the study
• Unwilling to provide consent and those who cannot be followed-up
 
Study visits
Following enrollment, participants will be seen by the study teams at 12 and 
24 months at a face to face meeting. Demographic data and socioeconomic 
status (occupation before retiring, economic status, formal and informal care) 
will be documented and followed up at each visit. Physical examination will 
be performed by medical doctors due to standardized procedure given in 
the visit protocol. Medical history and use of medication and adverse drug 
reactions classified according to the World Health Organization (WHO) 
definition37 will be collected during follow-up visits. During all face to face 
visits a comprehensive geriatric assessment (CGA) will be performed. Table 
2 shows all domains checked during study visits.38-51
  Healthcare resource consumption will be evaluated using a 
resource use questionnaire within a 6-month recall time-frame.49 Following 
information will be retrieved: previous physician visits (GPs, specialists, 
or physician at the Emergency Room), use of diagnostic tests and 
specialist clinic procedures, use of care services (e.g. Nurse home visit, 
Physiotherapy, Home help, Social transport, Day care center) and hospital 
admissions (number and duration of hospitalization, type of reimbursement). 
Furthermore, caregiver burden will be measured using the Zarit Burden 
Interview (ZBI).52
27
2
Screening for Chronic Kidney Disease
During enrollment and at the two face to face follow up visits blood and urine 
samples will be collected and analysed for serum creatinine, urinary albumin 
and albumin-to-creatinine ratio.
Table 2. Comprehensive Geriatric Assessment domains tested during the 
SCOPE project
• Basic (ADL) and Instrumental Activities of Daily Living (IADL)/selfreported  
disability 38,39
• Mini Mental State Examination (MMSE)/cognitive status 40
• 15-items Geriatric Depression Scale (GDS)/mood 41
• Cumulative Illness Rating Scale (CIRS)/overall comorbidity 42
• History of falls and incident falls
• Vision and hearing impairment will be coded on a scale from 0 (adequate) to 4 (no 
vision/hearing present) 43
• Lower urinary tract symptoms (LUTS): The presence of LUTS will be ascertained 
by asking the patient to rate on a 5-point (0–4) Likert scale how big a problem, if 
any, has each of the following items been during the last 4 weeks: 1. Dripping or 
leaking urine, 2. Pain or burning in urination, 3. Bleeding with urination, 4. Weak 
urine stream or incomplete emptying, 5. Waking up to urinate, 6. Need to urinate 
frequently during the day 44
• Nutritional status: anthropometric parameters (calf circumference, arm 
circumference, Body mass index (kg/m2), waist-hip ratio, waist-toheight ratio), Mini 
Nutritional Assessment (MNA) 45 and 24-h dietary recalla 46
• Short Physical Performance Battery (SPPB) 47
• Grip strength 48 measured by using JAMAR hydraulic dynamometer
• Bioelectrical impedance analysis (BIA)b 49 Muscle mass will be calculated using the 
Janssen et al. equation 50, using the instrument Akern BIA101
• Health related quality of life will be rated by the Euro-QoL 5D 
aData obtained from the 24-h dietary recall will be analyzed using nutritional databases suitable for 
the patient’s country. Following the analysis, a detailed report (containing levels of consumption 
of various nutrients and energy) will be available. This level will be compared with recommended 
levels of intake bBIA will not be performed in patients with pacemaker or implantable cardioverter 
defibrillator.
 
Telephone follow-up
At 6- and 18-month participants and/or caregivers will be interviewed by 
phone to collect information on vital and functional status and healthcare 
resource consumption. Changes in medical history and adverse drug 
reactions will also be collected.
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Laboratory parameters and biomarkers
Serum creatinine measurement will be standardised to Isotope-Dilution Mass 
Spectrometry at local level, when the method is available. Creatinine-based 
eGFR will be calculated using the Berlin Initiative Study 1 (BIS1) equation, 
which is the only method specifically developed in a population older than 
70 years.53 ESRD will be defined as GFR < 15 mL/min/1.73 m2 or dialysis.54 
In case of unavailability of standardized creatinine methodology at local 
level, this measurement will be made by INRCA laboratories afterwards. The 
panel of laboratory parameters to be measured at baseline, 12-month and 
24 months by local laboratories will also include: complete blood cells count, 
lipids profile, electrolytes, nutritional status, and urine analysis.
 The project will also include the collection of blood and urine 
samples to investigate existing and innovative biomarkers of kidney function. 
Existing biomarkers of CKD like Cystatin C (CysC), 55 β-Trace protein (BTP), 
also known as lipocalin prostaglandin D2 synthase 56,57 Beta2-microglobulin 
58 will be measured using published and established methods. Potential 
and new biomarkers will be also evaluated. Furthermore, the evaluation of 
experimental kidney damage biomarkers as well as untargeted analysis of 
metabolomics in serum and urine is currently be performed in ULSAM 59 and 
PIVUS 60 studies, in order to identify additional kidney damage biomarkers 
that may be validated in the SCOPE project. Table 3 shows an overview on 
current, alternative and innovative biomarkers for CKD whose applicability in 
old age will be investigated within the SCOPE project.
  The assessment of selected genetic and epigenetic parameters 
involved in hallmarks of aging will be also carried out to investigate their 
relationship with kidney function. This latter assessment will be limited to 
participants who signed a separate informed consent (patients not giving 
informed consent for genetic and epigenetic analysis will be retained in 
the main cohort study), and will include: DNA methylation, polymorphisms 
of mitochondrial DNA, polymorphisms of genes coding for proand anti-
inflammatory cytokines (IL-6, IL-1, TNF-alpha, IL-10, IL-2, IL-17, IL-8) 
and chemokines (MCP-1 and RANTES), polymorphisms associated with 
molecules involved in the pathogenesis of metabolic and neurodegenerative 
diseases such as insulin and IGF-1 signaling pathway and APOE, Klotho, 
mTOR, and whole genome analysis by Affymetrix Chip Array 6.0.
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Table 3. Biomarkers research in the SCOPE project
Current screening 
methodsa 
Alternative screening 
methodsb
Innovative screening 
methodsb
Serum creatinine Serum cystatin C Serum fibroblast growth 
factor 23 
Creatinine-based eGFR Serum ß-trace protein Serum and urinary soluble 
TNF receptor 1 
Urinary albumin Serum ß2-microglobulin Serum and urinary soluble 
TNF receptor 2 
Albumin-to-creatinine ratio Serum and urinary 
osteopontin 
Serum penthraxin 3 
Serum and urinary endostatin 
Serum and urinary TIM-1 
(KIM-1) 
Serum TRAIL R2 
Serum and urinary endostatin
acurrent screening measures will be assessed at local laboratories and are immediately available 
after enrollment and follow-up visits; balternative and innovative screening measures 
Measured glomerular filtration rate
The assessment of measured glomerular filtration rate (mGFR) will be 
performed by single-dose inulin clearance.61,62 Participants will be asked 
to sign a separate informed consent to participate in this sub-study, while 
those not giving their consent will be retained in the main cohort study. The 
objective of this sub-study will be the derivation of new eGFR equation(s) 
based on already known and/or novel biomarkers. The accuracy of new 
equation(s) in predicting mGFR will represent the primary study endpoint. 
Accuracy will be assessed by P30 (percentage of estimates within 30% of 
the mGFR). A sample of 400 participants will enable us to detect a difference 
of 2% in P30 between the new equations (based on the innovative and novel 
biomarkers) and the BIS equations, with significance level 0.05 and power 
0.8 (considering a 1-sample and 1-sided test). In addition, we have evaluated 
that the sample will be sufficient to detect a statistically significant difference 
in 4,3 points in the Area under the ROC curve using the new equation(s) 
for discriminating participants below the critical threshold of 60 ml/min/ 
1.73 m2. Finally, the availability of mGFR in a subgroup of participants enrolled 
in the study will be used to investigate the relationship between innovative 
biomarkers and objectively measured kidney function.
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Study endpoints
The primary study endpoints will be the rate of eGFR decline and the 
incidence of ESRD. 
 The secondary endpoints will include measures of conventional 
and geriatric outcome measures, such as: rate of CKD complications 
(anemia, hyperphosphatemia, acidosis, hypoalbuminemia, 
hyperparathyroidism, hyperkaliemia); rate of major comorbidities (e.g. 
hypertension and CV diseases);42 overall and CV mortality; adverse 
drug reactions (ADRs); self-reported disability and objectively measured 
physical performance decline;38,39,47 cognitive impairment;40 depression;41 
malnutrition/undernutrition;45,46 health-related quality of life;51 healthcare 
resource consumption, including the estimation of caregiver burden.52 
  Information on vital status during follow-up will be obtained by 
interviewing the patients and/or their formal and/ or informal caregivers. For 
mortality during the follow-up period, date, place and cause of death will be 
retrieved by certificates of death exhibited by relatives or caregivers.
Data management and statistics
The SCOPE project will enroll a total of 2450 participants. On the basis of 
the primary end-points, a sample of 1900 patients will be able to differentiate 
between two equally sized subgroups according to a standardized difference 
in yearly rate of GFR decline of 0.13 mL/min/1.73 m2 with a power of 80%. 
The same sample size allows to detect a hazard ratio of 1.2 in time-to-event 
analyses with 80% power for incidence of ESRD. Thus, even a 20% drop out 
rate will not affect statistical power of the study.
  Every effort will be made to collect all data at the specified 
time points. In the case of missing (and not recoverable) data on 
primary endpoints, we will make the assumption that data are missing 
completely at random. Analyses will be carried out applying the list-
wise deletion of cases with missing values in order to obtain unbiased 
estimations. Multiple imputation of missing data will be applied only 
for secondary endpoints and co-variates when found appropriate. 
  For continuous outcomes, generalized mixed models will be used 
while for dichotomous outcomes, random effect logistic or Cox regression 
will be applied. Effect modification by age and gender will be investigated 
using multiplicative interaction analyses.
  Relevant exposure and co-variates will be selected based on 
plausible underlying hypothesis. Directed acyclic graphs may be used in order 
to create parsimonious multivariable models with minimized confounding. 
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If appropriate, repeated measurements of exposure and co-variates will be 
included in the models.
Economic monitoring
The economic analysis of the SCOPE project will include: i) cost of screening/
diagnosis; ii) cost of follow-up (e.g. pharmacological treatment, specialist visits, 
laboratory visits over the 2-year follow-up); iii) cost of CKD complications (e.g. 
emergency room access, hospital admission, haemodialysis, etc.); iv) other 
health-related costs (e.g. hospital out-patient care referrals, nursing home 
placements, use of home care services). With this analysis, it will be possible 
to determine main predictors of costs in CKD using multivariate regression 
and to establish cost-effective ratio of the intervention (overall healthcare 
costs, divided by efficacy, expressed as survival or quality-adjusted survival).
  In order to assess the cost-benefit profile of the screening program 
on a longer time horizon, clinical and economic results of the SCOPE project 
will be used to run a projection (10–15 years) using Markov modelling. The 
analysis consists in evaluating a hypothetical cohort of CKD patients, whose 
healthcare status is categorized into different initial Markov states, based on 
CKD biomarkers. Patients can move from one state to another, according to 
certain probabilities that will be derived from the SCOPE project, and can 
develop complications, such as cardiovascular morbidity, renal failure and 
need of dialysis, CKD related and non-related death.
Discussion
The SCOPE study is one of the largest prospective observational cohort 
studies aimed at screening for CKD among older persons across Europe. 
The current paper outlines the study protocol including statistical analysis of 
data, risk prediction modeling and economic evaluation of costs arising from 
CKD during the advanced ageing process.
  The strength of the protocol outlined in this paper is the real life setting 
for recruitment of participants. All persons with age ≥ 75 years attending the 
outpatient services at participating institutions will be requested to participate 
in the study. No other inclusion criteria will be considered. This seems the 
primary strength of the SCOPE study. The collection of real life data in a 
longitudinal fashion over a two- years period of time will allow insight on the 
impact of renal function on the management and advanced care planning of 
older subjects prone to renal impairment.
  It is expected that many of the participants enrolled will be affected by 
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multimorbidity.63 The impact of disease clusters and management strategies 
from experts in the field of nephrology and geriatrics will open access to 
comparative effectiveness analysis of data and interventions.64 People older 
than 75 years or people with impaired renal function have so far been rarely 
included into clinical trials. Aging population heralds a new geriatric “reality”, 
namely an increase in older adults with CKD. Conversely, many older adults 
are living healthy and active, even with several chronic conditions. In this 
context longitudinal epidemiological studies are extremely valuable tools in 
observational research and have many uses and strengths.65
  Multimorbidity, and in this context CKD have been shown to impact 
functional status, especially of older patients.65 The systematic use of a CGA 
makes possible the investigation of multiple domains of health status in older 
persons. CGA is part of clinical practice of Geriatric Medicine66 and is also 
useful in research investigating consequences of CKD67,68 since it has been 
shown to affect different kind of outcomes relevant to older people. The 
inclusion of functional domains, as recently postulated by the World Health 
Organization (WHO)69 in the design of screening models for CKD in older 
persons aligns the SCOPE projects with future demands for all Health Care 
systems around the globe.70,71 Health care is currently provided and funded on 
a disease-centered approach in many health care systems. The inclusion of 
CGA in the longitudinal evaluation of study participants of the SCOPE project 
will allow a more patient-centered and individualized approach for screening 
and advanced care planning for older subjects prone to kidney function 
decline.31,68 Furthermore, the search for biomarkers which are less influenced 
by muscle mass and more accurate in predicting outcomes compared to 
circulating creatinine is of special interest and will be further investigated. 
Thus, combining the use of CGA and the investigation of novel and existing 
independent biomarkers in within the SCOPE project, could help in building 
new evidence in the development of recommendations and guidelines for a 
patient-centered approach in the screening and management of older people 
at risk for CKD.
  The alignment of an economic evaluation of care pathways and 
histories of study participants during the study period will give new input for 
care providers and planners in different health care and funding systems. 
Inclusion of costs of screening to achieve accurate diagnosis of CKD and 
related follow-up costs (e.g. pharmacological treatment, specialist visits, 
laboratory visits over the 2-year follow-up) will answer current call for actions 
coming from different bodies.72 The focus on CKD related consumption of 
healthcare resources (e.g. emergency room access, hospital admission, 
hospital out-patient care referrals, nursing home placements, use of home 
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care services and others) using Markov modelling will provide key information 
for developments in public health.
  Major drawback or limitation of the project is the lack of standardized 
management and care plans for older people currently available for all 
participating centres. Centres enrolling participants in the SCOPE projects 
are highly experienced in the management of older multimorbidity subjects at 
risk for renal impairment and related clinical complications, including changes 
in functional status. Guidelines on CKD management are mainly disease-
centred and put a focus on morbidities and mortality. It is to be foreseen that 
the care pathways for participants will therefore still be tailored individually 
and according to needs, driven by expertise of staff in the participating 
centres. However, important information may be expected though, as the 
implementation of the CGA per se into care pathways has already been 
proven effective.66 It seems noteworthy that the individualized care approach 
during complex care management of older subjects is part of daily routine 
in geriatric medicine. Alignment of care processes along CGA results seems 
feasible in the context of current scientific evidence.
  In conclusion, the SCOPE project will close essential gaps in the 
care of older people with declining kidney function. Due to the extremely 
comprehensive study setting and data analysis it is to be expected that 
evidence arising from the SCOPE project will impact the management of older 
people suffering from CKD, as well as the quality of care delivered for older 
subjects at risk for CKD in daily routine. The high quality of data retrieved 
will however, also open doors for new research and innovation in the field of 
nephrology and geriatrics. Building on solid evidence arising from the current 
project, SCOPE will support the development of European recommendations 
and guidelines, as well as a European education program in the field of 
screening and management of CKD in older adults across Europe.
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3.1
Clinical implications of 
estimating glomerular 
filtration rate in older adults 
A. Corsonello, R. Roller-Wirnsberger, G. Wirnsberger, J. Ärnlöv, A. Carlsson, 
L. Tap, F. Mattace-Raso, F. Formiga, R. Moreno-Gonzalez, C. Weingart, 
C. Sieber, T. Kostka, A. Guligowska, P. Gil, S. Lainez Martinez, 
R. Artzi-Medvedik, I. Melzer, F. Lattanzio, on behalf of SCOPE investigators 
Clinical implications of estimating glomerular filtration rate with three 
different equations among older people. Preliminary results of the project 
“Screening for Chronic Kidney Disease among Older People across Europe 
(SCOPE)” 
 
Journal of Clinical Medicine, Jan. 2020
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Abstract
We aimed at investigating to what extent CKD may be staged interchangeably 
by three different eGFR equations in older people, and evaluating the source 
of discrepancies among equations in a population of 2257 patients older than 
75 years enrolled in a multicenter observational study. eGFR was calculated 
by CKD-EPI, BIS and FAS equations. 
 Statistical analysis was carried out by Bland–Altman analysis. κ 
statistic was used to quantify the agreement between equations in classifying 
CKD stages. The impact of selected variables on the difference among 
equations was graphically explored. 
 The average difference between BIS and FAS was -0.24 (95% limits 
of agreement (95%LA = -4.64–4.14) mL/min/1.73 m2. The difference between 
CKD-EPI and BIS and between CKD-EPI and FAS was 8.97 (95%LA = -2.90–
20.84) and 8.72 (95%LA = -2.11–19.56) mL/min/1.73 m2, respectively. As 
regards CKD stage classification, κ value was 0.47 for both CKD-EPI vs. FAS 
and CKD-EPI vs. BIS, while BIS and FAS had similar classificatory properties (κ 
= 0.90). Muscle mass was found related to the difference between CKD-EPI and 
BIS (R2 = 0.11) or FAS (R2 = 0.14), but not to the difference between BIS and FAS. 
 In conclusion, CKD-EPI and BIS/FAS equations are not 
interchangeable to assess eGFR among older people. Muscle mass may 
represent a relevant source of discrepancy among eGFR equations. 
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Introduction
Estimated glomerular filtration rate (eGFR) equations are routinely used for 
clinical assessment of kidney function, despite their accuracy among older 
patients still being a matter of debate. Identifying appropriate filtration markers 
and estimating equations for older and especially frail older people has come 
into focus and is of clinical as well as public interest as the prevalence of 
chronic kidney disease (CKD) is known to increase with age and to impact 
health status and survival in several different populations.1,2 Timely detection of 
CKD allows to contrast some pathogenetic mechanisms such as uncontrolled 
hypertension or, in diabetic nephropathy, glomerular hyperfiltration in order to 
slow kidney function decline.3 Importantly, it also allows to tailor the dosage 
of kidney-cleared medications, as well as CKD stage-specific interventions.4 
 To address current inconsistencies across recently published studies 
on determination of kidney function in older patients, it seems necessary to 
consider different statistical approaches, laboratory assays used to measure 
creatinine and specimen collection, handling, and storage. Furthermore, the 
impact of parameters like muscle mass, may impact internal consistency of 
measurement of kidney function, especially in this cohort of older subjects.5 
Indeed, sarcopenia, which is commonly observed among frail older people, 
may reduce creatine production leading to low serum creatinine levels even 
despite a significantly reduced glomerular filtration rate (GFR).6 To this aim, 
several different eGFR equations have been developed and tested for these 
cohorts of patients.7-11 Since 2012, KDIGO has adopted The Chronic Kidney 
Disease Epidemiological Collaborative (CKD-EPI) equation, but it cannot be 
considered universal in clinical practice yet.4 This equation was developed 
from a population consisting of 8254 subjects pooled from 10 studies, 
including 13% of people aged >65 years and 28% diabetics, and externally 
validated in a population of 3896 subjects pooled from 16 other studies.8 The 
Berlin Initiative Study (BIS)9 has been developed to be used in elderly people, 
and Full Age Spectrum (FAS) equations for the whole life span adapting also 
for age and both equations have been externally validated against gold-
standard measured GFR.12,13 Several studies tried to compare the sensitivity 
of the different creatinine-based equations (CKD-EPI, BIS, FAS) in cohorts of 
older subjects14 with striking differences in results. Nevertheless, creatinine-
based eGFR is still the most widely used measure for clinical assessment of 
kidney function. Other biomarkers of kidney function, especially cystatin C, 
were investigated in an attempt to improve the accuracy of kidney function 
estimates. While the accuracy of equations including both creatinine and 
cystatin C in predicting measured GFR was found to be better than that 
observed with creatinine-based ones among older patients,15 the agreement 
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between equations was found to be only marginally improved16 and prognostic 
accuracy unchanged when adding cystatin C.17 Thus, the additional costs 
generated by cystatin C assessment may not be associated with a true 
improvement in clinical assessment of kidney function. Indeed, it has been 
suggested that cystatin C may be cost-effective in young adults where it 
can help to reduce the number of false positives, but not in individuals aged 
≥ 75 years.18
 Additionally, even the accuracy of cystatin C-based eGFR in 
predicting measured GFR was found to improve when including fat-free 
mass in kidney function assessment among older CKD patients.19
 It is therefore evident that a knowledge gap still exists and 
ongoing studies will likely help to bridge it.20 Meanwhile, creatinine-based eGFR 
remains the less expensive and most widely available screening measure of 
kidney function. 
  Considering albumin-to-creatinine ratio (ACR) for staging of chronic 
kidney disease, the picture in ageing patients in daily clinical practice becomes 
even more complex.21 Albuminuria and GFR are both relevant measures of the 
functionality of glomeruli. Albuminuria is mainly a measure of the glomerular 
capillary wall permeability to macro-molecules and increased albuminuria 
occurs earlier in the course of many kidney diseases compared to GFR decline.22 
Both parameters play an important role in detection and staging of CKD. The 
current evidence for the validity of these two surrogate markers for prediction 
and progression of CKD is stronger for GFR than for change of albuminuria 
over time.21 However, during ageing the sensitivity of GFR determination 
and mathematical models applied to measure creatinine in the available test 
systems are strongly impacted by muscle mass. As early detection of a decline 
in kidney function is a key element in clinical complex care management for 
many doctors, the aim of the present study was to test how the mathematical 
models for eGFR calculation are affected by muscle mass and function as 
measured with bio-impedance analysis (BIA) and short physical performance 
battery (SPPB),23 two simple tests applicable in daily clinical practice in a 
cohort of multi-morbid 75 years+ patients in different stages of CKD at time 
of inclusion. We also aimed at investigating how difference in eGFR between 
CKD-EPI, BIS and FAS formula may affect the predictive staging of patients 
when introducing ACR according to KDIGO guidelines.4
Materials and Methods  
The SCOPE study (grant agreement number 436849), is a multicenter 2-year 
prospective cohort study involving patients older than 75 years attending 
47
3
Estimating kidney function
geriatric and nephrology outpatient services in participating institutions in 
Austria, Germany, Israel, Italy, the Netherlands, Poland and Spain. 
 Methods of the SCOPE study have been extensively described 
elsewhere.20 Patients were requested to sign a written informed consent before 
entering the study. The study protocol was approved by ethics committees at 
all participating institutions, and complies with the Declaration of Helsinki and 
Good Clinical Practice Guidelines. Only baseline data are used in the present 
study.
 Overall, 2461 patients were initially enrolled in the study. Of them, 204 
patients were excluded from this study because of incomplete baseline data, 
thus leaving a final sample of 2257 patients to be included in the analysis. For 
testing the hypothesis of impact of muscle mass on detection of glomerular 
filtration rate, a sub-cohort of 1462/2257 participants was recruited for 
muscle mass measurements as outlined below. 
2.1. Study Variables
Serum creatinine was measured at local level by standard methods. 
Creatinine-based eGFR was calculated using the equations described in 
Table 1.
Table 1. Estimated glomerular filtration rate equations used in the present 
study
Reference Study Equation
CKD-EPI8
Women (Scr≤0.7) 
            (Scr>0.7)    
eGFR = 144 × (Scr/0.7)-0.329 × (0.993)Age 
eGFR = 144 × (Scr/0.7)-1.209 × (0.993)Age
Men (Scr≤0.9)     
         (Scr>0.9)    
eGFR = 141 × (Scr/0.9)-0.411 × (0.993)Age 
eGFR = 141 × (Scr/0.9)-1.209 × (0.993)Age 
BIS9 3736 × creatinine‐ 0.87 × age‐ 0.95 × 0.82(if women)
FAS11 [107.3/(creatinine/Q)] x 0.988(Age-40) for age>40 years 
Q=median Scr value for age-/sex-specific healthy populations
Abbreviations: Scr, serum creatinine in mg/dL; CKD-EPI, Chronic Kidney Disease–Epidemiologic 
Collaboration; BIS, Berlin Initiative Study; FAS, Full Age Spectrum.
Albumin in urine was detected by urine spot analysis and expressed as 
mg albumin per gram urine (mg/g); ACR was calculated according to 
KDIGO guidelines.4
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Variables included in further analysis were age, sex and Body Mass Index 
(BMI) using the formula recommended in the guidelines of the European 
Society of Clinical Nutrition (ESPEN).24
  Physical performance was included in the analysis for consideration 
of sarcopenia. Physical performance was measured by SPPB.25 The SPPB 
includes gait speed (usual time to walk 4 m), five chair-stands test (time to 
rise from a chair and return to the seated position five times without using 
arms), and balance test (ability to stand with the feet together in the side-by-
side, semi-tandem, and tandem positions). A score from 0 to 4 was assigned 
to performance on each task. Individuals received a score of 0 for each task 
they were unable to complete. Summing the three individual categorical 
scores, a summary performance score was created for each participant 
(range, 0–12), with higher scores indicating better lower body function.
  To further validate muscle mass measures in comparison to SPPB 
values in a sub-cohort of 1462 participants in the SCOPE study, BIA was 
carried out by Akern BIA101 with BodyGram PLUS software (Akern srl, 
Pontassieve (FI), Italy), and muscle mass was calculated using the Janssen 
et al. equation.26 BIA was not performed in patients with pacemaker or 
implantable cardioverter defibrillator. 
2.2. Analytic Approach
Statistical analysis was performed by SPSS Statistical Software Package for 
Win V21.0 (SPSS Inc, Chicago, IL, USA) and MedCalc (MedCalc software 
bv, Ostend, Belgium). To investigate the impact of selected study variables 
on differences among equations, we used a graphic approach by GraphPad
Prism 8 (GraphPad, San Diego, CA, USA).
  Demographic and clinical characteristics of participants were 
expressed by descriptive statistics and the prevalence of selected disease 
was counted and expressed in percent of people affected in the cohort. Non-
parametric tests were applied to calculate differences between groups.
  Crude correlation among glomerular filtration rate calculated by 
CKD-EPI, BIS and FAS equation was investigated graphically. Bland–Altman 
plots were generated to plot the difference CKD-EPI-BIS, CKD-EPI-FAS and 
BIS-FAS against the mean of the two estimates, respectively, or the whole 
cohort of participants. 
 Furthermore, the prevalence of CKD stages obtained with different 
equations was investigated adding ACR and creatinine based glomerular 
filtration rates according to KDIGO guidelines.4
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Cohen’s kappa (κ) was calculated to quantify the agreement between 
equations in identifying people with different degrees of kidney dysfunction 
(eGFR > 90, stage 1; 90–60, stage 2; 60–45, stage 3a; 45–30, stage 3b; and 
<30 mL/min/1.73 m2, stage 4–5). Finally, we also calculated the prevalence 
of each individual KDIGO stage of CKD based on eGFR and ACR. Analyses 
were further stratified by sex.
  Finally, to investigate the impact of sarcopenia on the observed 
difference among study equations, we used a graphic approach plotting 
the difference of the values obtained by two equations on the value of the 
variable of interest (BMI, SPPB or muscle mass) and using local regression 
techniques to fit a parametric or non-parametric curve smoothing the 
relationship between the two variables. We adapted our choice on the basis of 
the regression curve best fitting the given distribution to calculate regression 
analysis.
2.3. Ethical Statement
The study protocol was approved by ethics committees at all participating 
institutions, and complies with the Declaration of Helsinki and Good Clinical 
Practice Guidelines. Only baseline data are used in the present study. 
Ethics approvals have been obtained by Ethics Committees in participating 
institutions as follows:
• Italian National Research Center on Aging (INRCA), Italy, #2015 
0522 IN, 27 January 2016.
• University of Lodz, Poland, #RNN/314/15/KE, 17 November 2015.
• Medizinische Universität Graz, Austria, #28–314 ex 15/16, 5 August 
2016
• Erasmus Medical Center Rotterdam, The Netherland, #MEC-2016-
036 - #NL56039.078.15, v.4, 7 March 2016.
• Hospital Clínico San Carlos, Madrid, Spain, # 15/532-E_BC, 16 
September 2016
• Bellvitge University Hospital Barcellona, Spain, #PR204/15, 29 
January 2016.
• Friedrich-Alexander University Erlangen-Nürnberg, Germany, 
#340_15B, 21 January 2016.
• Helsinki committee in Maccabi Healthcare services, Bait Ba-lev, Bat 
Yam, Israel, #45/2016, 24 July 2016.
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Results
General characteristics of the study population are reported in Table 2. As 
may be seen from the Table, men and women were equally distributed in 
the SCOPE cohort at baseline (1256 women/1001 men) with a median age 
of 80.3 ± 4.1 years for women and 80.4 ± 4.1 years for men. Men differed 
from women with a significantly lower eGFR as determined by CKD-EPI, BIS 
and FAS equation (data see Table 2, significance for all equations applied 
p < 0.001), had a higher amount of muscle mass in average and performed 
significantly better in the SPPB (women SPPB 8.3 ± 3.1, men SPPB 9.3 ± 
2.7, p < 0.001). Diabetes (p < 0.001), heart failure (p = 0.004), atrial fibrillation 
(p = 0.002) and myocardial infarction (p < 0.001) were more frequent in men 
than in women, arterial hypertension and stroke should a similar tendency 
without reaching the level of statistical significance. When comparing levels 
of GFR calculated by CKD-EPI, BIS and FAS formula for the whole cohort of 
participants the average eGFR value was higher with CKD-EPI compared to 
BIS (p < 0.001) and FAS (p < 0.001) equations for the whole cohort (see Table 
2 and Figure 1). 
 The three eGFR equations were strongly correlated each other, 
even if the correlations between CKD-EPI and BIS or FAS were less linear 
compared to that observed between BIS and FAS (Figure 1, panels A–C).
 The Bland–Altman analysis showed that the bias between BIS and 
FAS was very small(–0.24 mL/min/1.73 m2); greater difference was observed 
only for patients with high eGFR values (Figure 1, panel D). In contrast, 
there was a significant difference in calculated GFR values between CKD-
EPI and BIS and also between CKD-EPI and FAS (8.97 mL/min/1.73 m2 and 
8.72 mL/min/1.73 m2, respectively), peaking around 60 mL/min/1.73 m2 for 
both equations (CKD-EPI compared to BIS, CKD-EPI compared to FAS). 
Additionally, the 95% upper limits of agreement were 20.84 and 19.56 mL/
min/1.73 m2, respectively (Figure 1, panels E and F).
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Table 2. General characteristics of the study population in the SCOPE 
project
All patients
N=2257
Women
N=1256
Men
N=1001 p-value
Age, years 80.3±4.1 80.3±4.1 80.4±4.1 0.671
Sex, women, n (%) 1256 (55.6) - - -
Body mass index, kg/m2 27.8±4.7 27.9±4.9 27.6±4.5 0.153
Serum creatinine, mg/dL 1.11±0.56 0.93±0.41 1.33±0.64 <0.001
CKD-EPI eGFR, mL/min/1.73 m2 63.8±19.4 65.4±18.1 58.9±20.5 <0.001
90 or more, n (%) 43 (1.9) 32 (2.5) 11 (1.1)
60-89.9, n (%) 1335 (59.1) 807 (64.3) 528 (52.7)
45-59.9, n (%) 433 (19.2) 240 (19.1) 193 (19.3)
30-44.9, n (%) 271 (12.0) 112 (8.9) 159 (15.9)
<30, n (%) 175 (7.8) 65 (5.2) 110 (11.0)
BIS eGFR, mL/min/1.73 m2 54.6±15.2 55.5±14.8 51.1±14.9 <0.001
90 or more, n (%) 9 (0.4) 7 (0.6) 2 (0.2)
60-89.9, n (%) 759 (33.6) 471 (37.5) 288 (28.8)
45-59.9, n (%) 877 (38.9) 499 (39.7) 378 (37.8)
30-44.9, n (%) 451 (20.0) 213 (17.0) 238 (23.8)
<30, n (%) 161 (7.1) 66 (5.3) 95 (9.5)
FAS eGFR, mL/min/1.73 m2 55.0±17.3 55.4±16.9 51.7±17.0 <0.001
90 or more, n (%) 29 (1.3) 18 (1.4) 11 (1.1)
60-89.9, n (%) 775 (34.3) 467 (37.2) 308 (30.8)
45-59.9, n (%) 791 (35.0) 454 (36.1) 337 (33.7)
30-44.9, n (%) 450 (19.9) 227 (18.1) 223 (22.3)
<30, n (%) 212 (9.4) 90 (7.2) 122 (12.2)
ACR, mg/g 100±480 77.1±390 177±599 <0.001
<30, n (%) 1648 (73.0) 992 (79.0) 656 (65.5)
30-300, n (%) 458 (20.3) 216 (17.2) 242 (24.2)
>300, n (%) 151 (6.7) 48 (3.8) 103 (10.3)
Muscle mass, kg (N=1,462) 22.7±6.8 18.0±3.8 29.0±4.4 <0.001
SPPB, score 8.7±2.9 8.3±3.1 9.3±2.7 <0.001
Hypertension, n (%) 1734 (76.8) 972 (76.6) 772 (77.1) 0.767
Diabetes Mellitus, n (%) 569 (25.2) 264 (21.0) 305 (30.5) <0.001
Heart Failure, n (%) 373 (16.5) 182 (14.5) 191 (19.1) 0.004
Atrial fibrillation, n (%) 344 (15.2) 165 (1.1) 179 (17.9) 0.002
Myocardial infarction, n (%) 217 (9.6) 75 (6.0) 142 (14.2) <0.001
Stroke, n (%) 131 (5.8) 61 (4.9) 70 (7.0) 0.031
Notes: continuous variables are expressed as mean±SD. Continuous values were compared 
between men and women using the independent t-test, categorical values were compared 
between men and women using the chi-square test. Abbreviations: CKD-EPI, Chronic Kidney 
Disease-Epidemiology collaboration ; eGFR, estimated Glomerular Filtration Rate; BIS, Berlin 
Initiative Study; FAS, Full Age Spectrum; ACR, Albumin-to-Creatinine Ratio; SPPB, Short 
Physical Performance Battery.  
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Figure 1. Crude correlations among eGFR equations (A,B,C) and Bland-
Altman analysis (D,E,F)
Notes: In panel A-C, R² represents the square of the crude correlation coefficient of x and y. 
In panel D-F, the bland-altman method was used to calculate the mean difference between 
two equations (bias) and the corresponding 95% limits of agreement. Abbreviations: eGFR, 
estimated Glomerular Filtration Rate; FAS, Full Age Spectrum; BIS, Berlin Initiative Study; CKD-
EPI, Chronic Kidney Disease-Epidemiology collaboration.
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Properties of eGFR equations to classify and stage CKD were significantly 
different (Tables 3–5). The prevalence of stage 2 was 59.1% according to 
CKD-EPI, 33.6% according to BIS and 34.3% according to FAS, while the 
corresponding figures for stage 3a and 3b were 19.2%, 38.9%, and 35.0%, 
and 12.0%, 20.0% and 19.9%, respectively (Table 2). Overall, κ value was 
0.47 for both CKD-EPI vs. FAS and CKD-EPI vs. BIS, while the classificatory 
properties of BIS and FAS were found to be very similar (κ = 0.90) (Table 3). 
When applying the KDIGO stratification system to our study population, the 
prevalence of stage 2 was much more prevalent with CKD-EPI compared to 
FAS or BIS among patients without proteinuria or with moderate proteinuria, 
while differences among equations were smaller in patients with severe 
proteinuria (Table 3).
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Table 3. Prevalence of KDIGO stages with three different equations stratified 
by sex
eGFR 
values
All patients, N=2257 
ACR (mg/g)
Men, N=1001 
ACR (mg/g)
Women, N=1256 
ACR (mg/g)
CKD-EPI <30 30-300 >300 <30 30-
300
>300 <30 30-
300
>300
>90 35
2.1%
7
1.5%
1
0.7%
8
1.2%
3
1.3%
0 27
2.7%
4
1.8%
1
2.1%
60-89.9 1133
68.8%
188
41.3%
13
8.6%
433
65.9%
86
36.1%
9
8.7%
700
70.7%
102
47.0%
4
8.3%
45-59.9 311
18.9%
98
21.5%
24
15.8%
128
19.5%
50
21.0%
15
14.4%
183
18.5%
48
22.1%
9
18.8%
30-44.9 133
8.1%
84
18.5%
51
33.6%
69
10.5%
52
21.8%
36
34.6%
64
6.5%
32
14.7%
15
31.3%
<30 35
2.1%
78
17.1%
63
41.4%
19
2.9%
47
19.7%
44
42.3%
19
2.9%
31
14.3%
19
39.6%
BIS
>90 6
0.3%
3
0.8%
0 1
0.2%
1
0.4%
0 5
0.5%
2
0.9%
0
60-89.9 655
39.8%
97
21.3%
7
4.6%
247
37.6%
37
15.5%
5
4.8%
408
41.3%
60
27.6%
2
4.2%
45-59.9 710
43.1%
143
31.4%
23
15.1%
285
43.4%
80
33.6%
12
11.5%
425
42.9%
63
29.0%
11
22.9%
30-44.9 244
14.8%
140
30.8%
64
42.1%
109
16.6%
79
33.2%
48
46.2%
135
13.6%
61
28.1%
16
33.3%
<30 32
1.9%
72
15.8%
58
38.2%
15
2.3%
41
17.2%
39
37.5%
17
1.7%
31
14.3%
19
39.6%
FAS
>90 22
1.3%
6
1.3%
1
0.7%
8
1.2%
3
1.3%
0 14
1.4%
3
1.4%
1
2.1%
60-89.9 669
40.7%
101
22.2%
6
3.9%
263
40.0%
42
17.6%
5
4.8%
406
41.1%
59
27.2%
1
2.1%
45-59.9 641
38.9%
131
28.8%
17
11.2%
254
38.7%
72
30.3%
9
8.7%
387
39.1%
59
27.2%
8
16.7%
30-44.9 267
16.2%
127
27.9%
53
34.9%
109
16.6%
72
30.3%
40
30.5%
158
16.0%
55
25.3%
13
27.1%
<30 48
2.9%
90
19.8%
75
49.3%
23
3.5%
49
20.6
50
48.1%
25
2.5%
41
18.9%
25
52.1%
Notes: eGFR values are expressed as mL/min/1.73m² and categorized according to KDIGO 
stages4: eGFR >90, stage 1; 60-89.9, stage 2; 45-59.9, stage 3a; 30-44.9, stage 3b; and <30, 
stage 4–5). Colour coding was used according to KDIGO4: Green = low risk, Yellow = moderately 
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increased risk, Orange = high risk, Red = very high risk. Prevalence is expressed as number 
and percentages. Abbreviations: eGFR, estimated Glomerular Filtration Rate; ACR, Albumin-
to-Creatinine Ratio; CKD-EPI, Chronic Kidney Disease-Epidemiology collaboration; BIS, Berlin 
Initiative Study; FAS, Full Age Spectrum.
It is worth noting that 574 (43%) out of 1335 patients classified in stage 2 by 
CKD-EPI were classified in stage 3a by FAS equation, and 216 out of 433 
(50%) patients classified in stage 3a by CKD-EPI were classified in stage 3b by 
FAS equation. Similar findings were obtained when comparing CKD-EPI and 
BIS equation, while such a difference was negligible when comparing BIS and 
FAS equations (Table 4). Finally, disagreement between CKD-EPI and FAS or 
BIS was more evident among women (Table 5) than men (Table 6).
 BMI and SPPB score were not significantly correlated with 
difference among equations (Figure 2, panels A-F). The analysis regarding 
muscle mass was limited to 1462 patients undergoing BIA during the 
enrolment visit. The relationship between muscle mass and BIS minus 
FAS was not significant. Conversely, CKD-EPI minus FAS and CKD-EPI 
minus BIS increased together with decreasing muscle mass (Figure 2, 
panels G-I).
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Table 4. Agreement among eGFR equations in all participants (n=2257)
CKD-EPI
>90 
(N=43)
60-89.9  
(N=1335)
45-59.9 
(N=433)
30-44.9 
(N=271)
<30 
 (N=175)
κ p
FAS
>90 29 
(67.4%)
0.47 0.001
60-89.9 14 
(32.6%)
761 
(57.0%)
45-59.9 574 
(43.0%)
217 
(50.1%)
30-44.9 216 
(49.9%)
234 
(86.3%)
<30 37 
(13.7%)
175 
(100%)
0.47 0.001
BIS
>90 9 
(20.9%)
60-89.9 34 
(79.1%)
725 
(54.3%)
45-59.9 610 
(45.7%)
267 
(61.7%)
30-44.9 166 
(38.3%)
267 
(98.5%)
18 
(10.3%)
<30 4  
(1.5%)
157 
(89.7%)
BIS
>90 
 (N=9)
60-89.9 
(N=759)
45-59.9 
(N=877)
30-44.9 
(N=451)
<30 
(N=161)
κ p
0.90 0.001
FAS
>90 9  
(100%)
20  
(2.6%)
60-89.9 738 
(97.2%)
37  
(4.2%)
45-59.9 1  
(0.1%)
790 
(90.1%)
30-44.9 50  
(5.7%)
400 
(88.7%)
<30 51 
(11.3%)
161 
(100%)
Notes: eGFR values are expressed as mL/min/1.73m² and categorized according to KDIGO 
stages4: eGFR >90, stage 1; 60-89.9, stage 2; 45-59.9, stage 3a; 30-44.9, stage 3b; and <30, stage 
4–5). Prevalence is expressed as number and percentages. Cohen’s kappa (κ) was calculated 
to quantify the agreement between equations with corresponding p-value. Abbreviations: 
eGFR, estimated Glomerular Filtration Rate; CKD-EPI, Chronic Kidney Disease-Epidemiology 
collaboration; BIS, Berlin Initiative Study; FAS, Full Age Spectrum.
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Table 5. Agreement among eGFR equations in women (n=1256)
CKD-EPI
>90  
(N=32)
60-89.9 
(N=807)
45-59.9 
(N=240)
30-44.9 
(N=112)
<30 
 (N=65)
κ p
FAS
>90 18 
(56.3%)
0.36 0.001
60-89.9 14 
(43.8%)
453 
(56.1%)
45-59.9 354 
(43.9%)
100 
(41.7%)
30-44.9 140 
(58.3%)
87 
(77.7%)
<30 25 
(22.3%)
65 
(100%)
0.41 0.001
BIS
>90 7  
(21.9%)
60-89.9 25 
(78.1%)
446 
(55.3%)
45-59.9 361 
(44.7%)
138 
(57.5%)
30-44.9 102 
(42.5%)
109 
(97.3%)
2  
(3.1%)
<30 3  
(2.7%)
63 
(96.9%)
BIS
>90  
(N=7)
60-89.9 
(N=471)
45-59.9 
(N=499)
30-44.9 
(N=213)
<30 
(N=66)
κ p
0.90 0.001
FAS
>90 7  
(100%)
11  
(2.3%)
60-89.9 459 
(97.5%)
8  
(1.6%)
45-59.9 1  
(0.2%)
453 
(90.8%)
30-44.9 38  
(7.6%)
188 
(88.7%)
<30 24 
(11.3%)
66 
(100%)
Notes: eGFR values are expressed as mL/min/1.73m² and categorized according to KDIGO 
stages4: eGFR >90, stage 1; 60-89.9, stage 2; 45-59.9, stage 3a; 30-44.9, stage 3b; and <30, stage 
4–5). Prevalence is expressed as number and percentages. Cohen’s kappa (κ) was calculated 
to quantify the agreement between equations with corresponding p-value.  Abbreviations: 
eGFR, estimated Glomerular Filtration Rate; CKD-EPI, Chronic Kidney Disease-Epidemiology 
collaboration; BIS, Berlin Initiative Study; FAS, Full Age Spectrum
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Table 6. Agreement among eGFR equations in men (n=1001)
CKD-EPI
>90 
(N=11)
60-89.9 
(N=528)
45-59.9
(N=193)
30-44.9 
(N=159)
<30 
 (N=110)
κ p
FAS
>90 11  
(100%)
0.57 0.001
60-89.9 308 
(58.3%)
45-59.9 220 
(41.7%)
117 
(60.6%)
30-44.9 76 
(39.4%)
147 
(92.5%)
<30 12  
(7.5%)
110 
(100%)
0.53 0.001
BIS
>90 2  
(18.2%)
60-89.9 9  
(81.8%)
279 
(52.8%)
45-59.9 249 
(47.2%)
129 
(66.8%)
30-44.9 64 
(33.2%)
158 
(99.4%)
16 
(14.5%)
<30 1  
(0.6%)
94 
(85.5%)
BIS
>90 
(N=2)
60-89.9 
(N=288)
45-59.9 
(N=378)
30-44.9 
(N=238)
<30 
(N=95)
κ p
0.89 0.001
FAS
>90 2  
(100%)
9  
(3.1%)
60-89.9 279 
(96.9%)
29  
(7.7%)
45-59.9 337 
(89.2%)
30-44.9 12  
(3.2%)
211 
(88.7%)
<30 27 
(11.3%)
95  
(100%)
Notes: eGFR values are expressed as mL/min/1.73m² and categorized according to KDIGO 
stages4: eGFR >90, stage 1; 60-89.9, stage 2; 45-59.9, stage 3a; 30-44.9, stage 3b; and 
<30, stage 4–5). Prevalence is expressed as number and percentages. Cohen’s kappa (κ) 
was calculated to quantify the agreement between equations with corresponding p-value. 
Abbreviations: eGFR, estimated Glomerular Filtration Rate; CKD-EPI, Chronic Kidney 
Disease-Epidemiology collaboration; BIS, Berlin Initiative Study; FAS, Full Age Spectrum 
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Figure 2. Graphical analysis of the impact of body mass index (panels A–C), 
physical performance (Panels D–F) and muscle mass* (Panels G–I) on the 
difference among eGFR equations 
Notes: *n=1462.  R² represents the square of the crude correlation coefficient of x and y. 
Abbreviations: eGFR, estimated glomerular filtration rate; BIS, Berlin Initiative Study; FAS, Full 
Age Spectrum, CKD-EPI, Chronic Kidney Disease-Epidemiology collaboration; BMI, body mass 
index; SPPB, short physical performance battery. 
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4. Discussion
Overall, our findings clearly show that BIS and FAS equations may provide 
different estimates of GFR compared to CKD-EPI equation in a population 
of older outpatients. It is important to notice that the greatest difference is 
observed for eGFR values around 60 mL/min/1.73 m2. The fact that this range 
of GFR is of potential interest in daily clinical practice management of older 
subjects puts our results in the focus of experts as well as clinicians.
 Determination of kidney function has been a topic of discussion 
among experts and may impact clinical management of patients as well as 
setting endpoints in future clinical studies.21 Over the past decade, several 
attempts have been made to test creatinine-based mathematical models 
for determination of kidney function in different cohorts of patients and 
healthy subjects.14 Furthermore, parameters like age, sex, muscle mass, may 
impact internal consistency of measurements of kidney function, especially 
in this cohort of older subjects.5 It has been speculated that loss of muscle 
mass, which is common in the frail older persons, may impact production of 
creatine and ensuing low levels of serum creatinine even despite a depressed 
glomerular filtration rate (GFR).6
  To date, only few studies including multimorbid older subjects, also 
including those with physical functional deficits, have focused on this burning 
issue for clinical practice, but also research. The older people participating in 
the SCOPE study represent a rich source and wealth in several dimensions: 
people older than 75 years and living in a community were recruited and 
followed up for two years on a voluntary basis in this observational study with 
a wide recruitment frame and only few exclusion criteria.20 Not surprisingly, 
women are outnumbering men participants as it is a fact that women account 
for a higher percentage of older community dwelling persons in many EU 
countries nowadays.27 The very open inclusion criteria concerning kidney 
function (only excluding people with an initial eGFR < 15 mL/min-1 during 
recruitment phase) furthermore contributed to a real-life picture when treating 
older people in clinical practice in the EU.
  Given the fact that recent data on prevalence of CKD clearly 
demonstrated a sex bias for CKD, men being at higher risk for development 
of CKD,28 it was the major interest of the study team to also address sex 
differences when looking at the impact of the method used to calculate 
eGFR on staging of CKD based on creatinine- and albuminuria-based 
guidelines.4 The access to data from a cohort older than 75 years, many of 
them multimorbid and prone to loss of muscle mass, made it possible for the 
consortium to further test the hypothesis that impaired physical performance 
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and loss of muscle mass may impact the degree of agreement among eGFR 
equations in this cohort of older European citizens.20
  Several studies reported on discrepancies between eGFR values 
obtained with different equations, but only a few of them included the most 
recently published BIS and FAS equations at the same time.A former study 
showed that the average difference between creatinine-based CKD-EPI and 
BIS was 9.5 mL/min/1.73m2 in a population of 828 community-dwelling older 
people,16 which is very close to the 8.97 mL/min/1.73 m2 difference observed 
in the present study. The average 8.72 mL/min/1.73 m2 difference between 
CKD-EPI and FAS, as well as the negligible average difference between BIS 
and FAS are not surprising given the fact that FAS has been designed to 
match the BIS equation for ages >70 years.11 Additionally, FAS was recently 
reported to predict eGFR calculated by the creatinine/cystatin C-based CKD-
EPI equation with a median bias 10.2 mL/min/1.73 m2 (95%CI = 9.2–10.9) 
in a population of 1913 Chinese CKD patients aged 50.3±18.2 years.29 
Interestingly, the above differences were observed despite the good average 
diagnostic performance of CKD-EPI, BIS and FAS equations in predicting 
measured GFR. Indeed, da Silva Selistre recently reported that the median 
difference between CKD-EPI and FAS in predicting measured GFR was –2.0 
(95%CI = –3.5; –2.5) mL/min/1.73 m2, and the corresponding figure for the 
difference between CKD-EPI and BIS was 0.0 (95%CI = –1.5; 0.5). Thus, if 
we consider such a small difference between equations with respect to gold-
standard measured GFR, the average differences between CKD-EPI and BIS 
or FAS equations observed in our study would be unexpected.
  Nevertheless, eGFR equations are known to work well in populations 
for which they had been developed.30 The FAS equation was originally 
developed in a life-span perspective to allow eGFR calculation from 
childhood to older age,11 while the BIS equation was specifically developed 
in a population of people aged 70 years or more.9 At variance, CKD-EPI 
was developed in a pooled population with a wide age range (50±15 years), 
but only 13.0% of the development and validation population was aged 65 
years or more.8 On the other hand, our study confirms the good agreement 
between BIS and FAS equations, which, given their history and intention of 
development, is less surprising. 
   As regards potential sources of discrepancy among eGFR equations, 
serum creatinine, and muscle mass are main correlates also impacting 
known sex differences of the CKD-EPI and BIS or FAS equations. Finally, 
differences among eGFR equations are much more evident among women 
and significantly impact the KDIGO staging of CKD. It is therefore evident that 
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choosing older people to undergo CKD-related diagnostic procedures and/
or treatments will change depending on which equation is used to assess 
eGFR. 
  In our analysis, we tried to estimate the agreement in terms of CKD 
staging between equations, i.e., from the practitioner’s perspective. Indeed, 
“misclassification” has important clinical implications in terms of staging and 
management of CKD, especially between stage 2 and 3 CKD. Given the high 
prevalence of stage 3 CKD and the highly variable risk of mortality as well as 
other negative outcomes in this group, current guidelines include a distinction 
between CKD stage 3a and 3b.4 The risk associated with stage 3a CKD in older 
patients is still under discussion,31 and GFR level at which the risk of mortality 
starts to increase may be lower among older patients compared to younger 
ones.32 Additionally, older people with eGFR<60 mL/min/1.73 m2 exhibit a 
slow progression of CKD.33 However, current guidelines do not calibrate 
the definition of CKD for age and suggest many stage-specific therapeutic 
measures.4 Relative “misclassification” is also more common in women in our 
study. Sex represents a relevant non-GFR determinant of serum creatinine,34 
and clinically relevant discrepancies between eGFR equations were found to 
be more frequent among women aged 75 or more.35
   Failure to correctly classify older CKD patients also poses significant 
challenges in managing kidney cleared medications, especially among older 
patients with multiple chronic diseases treated with polypharmacy regimens. 
As an example, guideline recommendations suggest careful dosing of 
several hypoglycemic agents in patients with eGFR <60 mL/min/1.73 m2.36 
Finally, disagreement between equations may have important implications 
when prescribing or dosing several other drugs,37 including direct oral 
anticoagulants,38 in terms of missing contraindication or dose reduction 
recommendation on one side, and underuse or underdosing on the other 
side.
  Additionally, the difference between CKD-EPI and BIS or FAS equations 
increased together with reducing ACR and muscle mass in our study. The 
greatest difference between CKD-EPI and BIS or FAS equations was observed 
for lower ACR and muscle mass values. Creatinine is a metabolic product of 
creatine and phosphocreatine arising from the muscle compartment which 
is directly related to muscle mass,39 and albuminuria also is known to be 
associated with muscle mass. Sarcopenia is a common occurrence among 
older adults and its prevalence increases dramatically with decreasing kidney 
function. In CKD patients, the prevalence of sarcopenia was found to be 
approximately 40% for eGFR = 60–89 mL/min/1.73 m2, and approximately 
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60% for eGFR < 60 mL/min/1.73 m2.40 Thus, the above findings together with 
the observation that the difference between BIS and FAS was only  marginally 
affected by serum creatinine, ACR and muscle mass in the present study, 
suggest that the population of the SCOPE study may be on one side very 
similar to that used for the development of the BIS and FAS equations (i.e., 
an older population aged 75 or more that includes sarcopenic patients), and 
on the other side very di_erent from that used for the development of the 
CKD-EPI equation (i.e., a younger population including only 13% of people 
aged 65 or more). Finally, part of the sex differences observed in our study for 
the different GFR equations may be attributed to the lower muscle mass of 
women participating in the SCOPE study (Table 1).41
Limitations and Strengths
Some limitations of the present study deserve consideration. Our study did 
not include a direct measurement of GFR. Thus, we cannot draw any definitive 
conclusion about the diagnostic accuracy of the study equations against a 
gold standard assessment. Indeed, experimental evidence suggests that 
intravenous inulin and iohexol may partially undergo extrarenal clearance,42,43 
which may represent a not negligible potential source of error when measuring 
GFR for developing or validating eGFR equations. Nevertheless, the amount 
of extrarenal clearance of GFR markers in humans is unknown and is worthy 
of future investigations. Additionally, patients with eGFR < 15 mL/min/1.73 
m2 were excluded. Nevertheless, this limitation is likely to have a minor role 
in the present study given the good agreement observed among equations in 
patients with severe CKD.
  This study also has important strengths, including the enrollment 
of a real-world population of older outpatients and the opportunity to 
investigate the impact of objectively measured physical performance and 
body composition on the observed difference among equations.
Conclusions
Our results show that CKD-EPI and BIS or FAS equations cannot be considered 
interchangeable to assess eGFR in a population of older outpatients. Indeed, 
despite a fair overall concordance, the respective eGFRs differ significantly in 
the range of GFR corresponding to CKD stages 2–3b, and this could have a 
dramatic impact on our diagnostic and therapeutic approach. While our study 
does not allow to draw a definitive conclusion on diagnostic accuracy of 
each individual equation, BIS and FAS equations provided very similar eGFR 
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values and the difference between BIS and FAS seems to be unaffected by 
muscle mass. At variance, muscle mass seems to represent a major source 
of discrepancy between CKD-EPI and BIS or FAS. Thus, our findings suggest 
that the two most recent BIS and FAS equations specifically developed 
in older patients may be very useful for clinical assessment of eGFR in a 
population of older outpatients aged >75 years. Additionally, their substantial 
overlap would minimize discrepancy issues when monitoring progression of 
CKD. Finally, the impact of muscle mass on CKD staging and its predictivity, 
as well as the clinical usefulness of muscle mass assessment to decide which 
equation to use in clinical practice deserve to be further investigated.
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Abstract
Background: studies suggest that estimated glomerular filtration rate 
(eGFR) is less reliable in older persons and that a low serum-creatinine might 
reflect reduced muscle mass rather than high kidney function. This study 
investigates the possible relationship between eGFR and multiple elements 
of physical performance in older fallers. 
Methods: baseline data of the IMPROveFALL-study were examined in 
participants ≥65 years. Serum-creatinine based eGFR was classified as 
normal (≥90 ml/min), mildly reduced (60–89 ml/min) or moderately–severely 
reduced (<60 ml/ min). Timed-Up-and-Go-test and Five-Times-Sit-to-Stand-
test were used to assess mobility; calf circumference and handgrip strength 
to assess muscle status. Ancova models adjusted for age, sex, Charlson 
comorbidity index and body mass index were performed. 
Results: a total of 578 participants were included. Participants with a normal 
eGFR had lower handgrip strength than those with a mildly reduced eGFR 
(−9.5%, P < 0.001) and those with a moderately–severely reduced eGFR 
(−6.3%, P = 0.033) with mean strengths of 23.4, 25.8 and 24.9 kg, respectively. 
Participants with a normal eGFR had a smaller calf circumference than those 
with a mildly reduced eGFR (35.5 versus 36.5 cm, P = 0.006). Mean time to 
complete the mobility tests did not differ.
Conclusions: in this study we found that older fallers with an eGFR ≥ 90 ml/
min had smaller calf circumference and up to 10% lower handgrip strength 
than those with a reduced eGFR. This lower muscle mass is likely to lead 
to an overestimation of kidney function. This outcome therefore supports 
the search for biomarkers independent of muscle mass to estimate kidney 
function in older persons.
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Introduction
The prevalence of chronic kidney disease (CKD) is rising, due to increased 
ageing of the population and an increase in the number of risk factors, such 
as obesity, diabetes and hypertension.1 The prevalence of CKD, defined as 
a glomerular filtration rate (GFR) <60 ml/min/1.73 m2,2 rises in older persons 
with a prevalence from <1% in persons under 35 years to more than 33% 
in persons aged 75 years and over.1,3,4 Additionally, CKD increases the 
risk of morbidity and mortality5,6 and negatively affects multiple aspects of 
functionality and daily performance.7-9
  In clinical practice, estimation of GFR (eGFR) is commonly used as a 
quick evaluation of kidney function.10,11 For estimating GFR, serum-creatinine 
(s-creatinine) is used as marker, despite the fact that it may be misleading in 
older persons due to a reduction in muscle mass with ageing.12 Recent studies 
have focussed on evaluation of new and independent filtration markers, such 
as serum cystatin C, ß-trace protein and ß2-microglobuline, to assess renal 
function and to improve risk prediction related to decreased GFR.13 However, 
in clinical practice s-creatinine based eGFR is still daily used. Therefore, it 
seems relevant to take a closer look at the accuracy of the s-creatinine based 
eGFR in older persons, since this estimation of renal function may be greatly 
influenced by muscle mass. Previous studies showed that low s-creatinine, 
resulting in higher eGFR values, partly reflects muscle atrophy and ‘frailty’ in 
older persons.14,15 In the oldest old community-dwelling persons ≥90 years, 
where the prevalence of sarcopenia is higher,12 a U-shaped relationship was 
found between eGFR and handgrip strength and mortality.14 These findings 
generate the hypothesis that sarcopenic persons, having low s-creatinine, 
might group in categories with high eGFR values.
  In this study we investigated whether s-creatinine based eGFR is 
associated with physical performance in persons aged 65 years and over 
who have fallen
Methods
Data collection
Baseline data from the Improving Medication Prescribing to reduce Risk Of 
FALLs (IMPROveFALL) study were analysed. The IMPROveFALL-study is a 
randomised multicentre trial investigating the effect of withdrawal of fall-risk 
increasing drugs versus ‘care as usual’ on reducing falls in community-dwelling 
persons. A detailed description of the methods can be found elsewhere.16 In 
summary, individuals aged ≥65 years who visited the Emergency Department 
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(ED) because of a fall were asked to participate. Individuals had a Mini-Mental 
State Examination (MMSE) score of at least 21 out of 30 points.17 The baseline 
visit took place within 2 months after ED attendance. The ethical committee 
of the Erasmus MC approved the study and all participants signed informed 
consent.
Covariates
Demographic data were collected from ED records. Medical history, use of 
medications, lifestyle factors and number of comorbidities were documented 
and Charlson comorbidity index (CCI) was determined. Height and weight 
were measured and body mass index (BMI) was calculated.
Biochemistry
S-creatinine, sex and age were used to calculate the eGFR in ml/min/1.73 
m2 with the Modification of Diet in Renal Disease (MDRD) Study formula 
widely used: 175 × (s-creatinine (μmol/l) × 0.0113)−1.154 × age−0.203 (years) × 
0.742 (if female). GFR was also estimated with the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) formula, because of the increasing 
use of this formula in general practice.18 Kidney function was classified 
as proposed by the National Kidney Foundation2 and slightly merged into 
the following three categories: normal (eGFR ≥ 90 ml/min/1.73 m2), mildly 
reduced (eGFR 60–89 ml/min/1.73 m2), moderately–severely reduced (eGFR 
15–59 ml/min/1.73 m2).
Physical performance
The Timed-Up-and-Go test (TUG) and the Five-Time-Sit-to-Stand test (FTSS) 
were used to assess mobility.19,20 Handgrip strength was measured to reflect 
muscle strength and calf circumference to reflect muscle mass. Handgrip 
strength is reported as a validated indicator for global muscle strength21 
and was measured with a hand-held dynamometer (Takei TKK 540, Takei 
Scientific Instruments Co., Ltd., Tokyo, Japan) in standing position with arms 
beside the body, using the maximum strength from four alternating (right–
left) attempts. For measuring calf circumference participants sat with a knee 
angle of 90° and the sole on the ground. The thickest part of both calves was 
measured with a measuring tape and the mean value was documented.
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Statistical analyses
Statistical analyses were performed using SPSS statistical package 21.0 
for Windows. Descriptive data for continues variables were presented as 
median and interquartile range (IQR). Numbers and percent prevalences 
were presented for dichotomous variables. Spearman’s correlation analyses 
were used to investigate the relation of age with s-creatinine, eGFR (MDRD 
and CKD-EPI formula) and physical performance. Missing performance test 
measures, mostly due to injuries following fall, were excluded from all related 
analyses. Because of a right-skewed distribution, outcomes of physical 
performance were log transformed using the natural log. In analyses of 
covariance we compared mean (natural log transformed) scores of physical 
performance tests across three categories of eGFR (eGFR ≥ 90 ml/min, eGFR 
60–89, eGFR < 60 ml/min). All models were adjusted for sex, age and CCI. 
Models investigating muscle mass and strength were also adjusted for BMI. 
We back transformed the results to the original scale. A two-tailed p < 0.05 
was defined as statistically significant.
Results
Overall, 616 participants were enroled in the IMPROveFALL-study; 
information on s-creatinine was obtained from 578 participants. Median age 
was 76.3 years (IQR: 70.2–81.6), 39% were men, 50% lived with a partner, 
72% were ADL independent and 58% were iADL independent. The 20% 
of the participants had diabetes mellitus, 21% had a history of coronary 
heart disease and 18% had a history of cancer. Using the MDRD-formula 
115 participants (19.9%) had a normal eGFR, 314 participants (54.3%) had 
a mildly reduced eGFR and 149 participants (25.8%) had a moderately–
severely reduced eGFR. Participants in the lowest category had a median 
eGFR of 50 ml/min (IQR: 41–55). When GFR was estimated with the CKD-
EPI formula, the categories were different with 11.4, 62.5 and 26.1% from 
highest to lowest eGFR, respectively. Median s-creatinine was 75.0 μmol/l 
(IQR: 65.0–93.0), median eGFR was 72.0 ml/min (IQR: 59.0–85.0) using the 
MDRD-formula and 73.7 ml/min (IQR: 59.2–84.9) using the CKD-EPI formula. 
Median time to complete the TUG was 10.0 s (IQR: 8.0–14.0) and 15.0 s 
(IQR: 12.0–20.0) for the FTSS. Median handgrip strength was 24.7 kg (IQR: 
19.9–32.3) and median calf circumference was 36.3 cm (IQR: 34.0–38.8). 
Characteristics of the participants are shown in Table 1.
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Table 1. Characteristics of the participants (n = 578)
Age in years 76.3 (70.2–81.6)
Men, n (%) 226 (39.1)
Education 
    ≤ 6 years, n (%)
    6 – 10 years, n (%)
    >10 years, n (%)
162 (27.9)
214 (37.0) 
203 (35.1)
Living with partner, n (%) 288 (49.8)
Widow(er), n (%) 194 (33.6)
Current smoker, n (%)
Former smoker, n (%)
64 (11.1)
201 (34.8)
ADL independent, n (%) 414 (72.0)
iADL independent, n (%) 331 (57.6)
BMI in kg/m² (n = 564) 27.1 (24.4–30.1)
MMSE in points 27.0 (25.0–29.0)
CCI score 2.0 (1.0–3.0)
    CCI 0, n (%) 
    CCI 1-2, n (%)
    CCI ≥3, n (%)
CHD, n (%)
Diabetes Mellitus, n (%)
Cancer, n (%)
Use of NSAIDs, n (%)
Use of diuretics, n (%)
Use of inhibitors of RAS, n (%)
113 (19.6) 
291 (50.3)
174 (30.1)
120 (20.8)
118 (20.4) 
106 (18.3)
13 (2.2)
56 (9.7) 
73 (12.6)
S-Creatinine in µmol/L 75.0 (65.0–93.0)
eGFR, MDRD in ml/min 
eGFR, CKD-EPI in ml/min 
72.0 (59.0–85.0)
73.7 (59.2–84.9) 
    eGFR ≥ 90 ml/min, n (%)
    eGFR 60 – 89 ml/min, n (%)
    eGFR < 60 ml/min, n (%)
TUG in seconds (n = 520)
FTSS in seconds (n = 479)
Handgrip strength in kg (n = 570)
Calf circumference in cm (n = 566)
115 (19.9) / 66 (11.4)*
314 (54.3) / 361 (62.5)*
149 (25.8) / 151 (26.1)*
10.0 (8.0–14.0)
15.0 (12.0–20.0)
24.7 (19.9–32.3)
36.3 (34.0–38.8)
Notes: continuous values are expressed as median and interquartile range. *Data on eGFR 
categories are expressed as number and percentage using the MDRD-formula and CKD-
EPI formula, respectively. Abbreviations: ADL, Activities of Daily Living;  iADL, Instrumental 
Activities of Daily Living; BMI, Body Mass Index; MMSE, Mini Mental State Examination; CCI, 
Charlson Comorbidity Index; CHD, Coronary Heart Disease; NSAIDs, Non-Steroidal Anti-
Inflammatory Drugs; RAS, Renin-Angiotensin System; S-Creatinine, serum-Creatinine; eGFR, 
estimated Glomerular Filtration Rate; MDRD, Modification of Diet in Renal Disease; CKD-EPI, 
Chronic Kidney Disease Epidemiology Collaboration; TUG, Timed Up and Go test; FTSS, Five-
Times-Sit-to-Stand test. 
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Age was associated with s-creatinine level (Spearman’s r = 0.190, P < 0.001), 
whereas an inverse association was found between age and eGFR using 
both MDRD and CKD-EPI formula (Spearman’s r = −0.274, P < 0.001 and 
Spearman’s r = −0.411, P < 0.001, respectively). MDRD eGFR and CKD-
EPI eGFR were strongly correlated (Spearman’s r = 0.979, P < 0.001). Age 
was also associated with reduced physical performance. An association 
was found between age and both mobility tests (TUG Spearman’s r = 0.333, 
P < 0.001; FTSS Spearman’s r = 0.203, P < 0.001). An inverse association 
was found between age and handgrip strength (Spearman’s r = −0.316, 
P < 0.001) and calf circumference (Spearman’s r = −0.337, P < 0.001). Results 
are shown in Figure 1.
Mean time to complete the mobility tests did not differ between 
categories. Mean time in seconds for the TUG, from lowest to highest 
category, was 11.4 (95% CI: 10.5–12.3), 10.4 (95% CI: 9.9–10.9) and 11.0 
(95% CI: 10.1–11.9), respectively. Mean time in seconds for the FTSS was 16.2 
(95% CI: 15.0–17.5), 16.0 (95% CI: 15.3–16.8) and 16.8 (95% CI: 15.5–18.2), 
respectively.
  Mean handgrip strength was 9.5% lower in participants with a normal 
eGFR (23.4 kg, 95% CI: 22.4–24.4) than those with a mildly reduced eGFR 
(25.8 kg, 95% CI: 25.2–26.5) and 6.3% lower than those with a moderately–
severely reduced eGFR (24.9 kg, 95% CI: 24.0–25.9). Mean calf circumference 
was 1.0 cm smaller in participants with a normal eGFR (35.5 cm, 95% CI: 
34.9–36.1) than those with a mildly reduced eGFR (36.5 cm, 95% CI: 36.1–
36.8). Mean calf circumference of participants with a moderately–severely 
reduced eGFR did not differ from those in other categories (36.0 cm, 95% 
CI: 35.5–36.6). Results of physical measures across categories of eGFR are 
shown in Figure 2.
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Figure 1. Correlations of age with renal function (A-D) and physical 
performance (E-H)
Abbreviations: S-Creatinine, serum-Creatinine; eGFR, estimated Glomerular Filtration Rate; 
MDRD, Modifi cation of Diet in Renal Disease; CKD-EPI, Chronic Kidney Disease Epidemiology 
Collaboration; TUG, Timed Up and Go test; FTSS, Five-Times-Sit-to-Stand test.
Figure 2. Mean values of physical performance across categories of eGFR 
using the MDRD-formula
77
3
Estimating kidney function
Notes: (a) Timed-Up-and-Go test (TUG), (b) Five-Times-Sit-to-Stand test (FTTS), (c) Handgrip 
strength, d. Calf circumference. eGFR values are expressed in mL/min. Dots represent mean 
values of back-transformed data, bars represent 95% confi dence intervals. Reported estimates 
are the mean diff erences of the higher category compared to the lower category expressed in 
percentage (with 95% confi dence interval of the diff erence). All analyses are adjusted for age, 
sex and Charlson comorbidity index. Analyses in (c, d) are also adjusted for body mass index. 
*P-value < 0.05; **P-value < 0.01; ***P-value < 0.001.
Estimates in models where the CKD-EPI formula was used, were slightly 
diff erent. However, the shape of the results remained unchanged. Mean 
handgrip strength in participants with an eGFR ≥ 90 ml/min was 8.7% lower 
(23.2 kg, 95% CI: 21.9–24.7) than those with a mildly reduced eGFR (25.5 
kg, 95% CI: 24.9–26.1). A mean diff erence of 7.2% and a tendency towards 
signifi cance was found when compared to those with a moderately–severely 
reduced eGFR (25.0 kg, 95% CI: 24.1–26.1). No diff erences were found in 
mean calf circumference, whereas the shape of the results were the same as 
in models where the MDRD-formula was used (data not shown).
Discussion
In this study we showed that older fallers with an eGFR ≥ 90 ml/min had less 
muscle mass and strength than older fallers with a reduced eGFR. Handgrip 
strength was found to be 10% lower in participants with a normal eGFR than 
those with a reduced eGFR. No association was found between eGFR and 
mobility.
 The consequences of kidney disease in older persons are frequently 
reported in studies.5-9 However, few studies focussed on the signifi cance 
of low s-creatinine and associated high eGFR. The implications of diff erent 
eGFR values were investigated in a large study population of community-
dwelling persons over the age of 50 in England.22 Cox et al. found both 
low and high eGFR, assessed by the MDRD-formula, to predict mortality. 
Cardiovascular diseases were the leading causes of mortality in persons with 
reduced eGFR. Interestingly, persons in high eGFR groups died of respiratory 
and neoplastic causes. The hypothesis was that respiratory and neoplastic 
diseases cause cachexia and sarcopenia and the associated low s-creatinine 
values resulting in a high eGFR. These outcomes support our fi ndings that 
high eGFR is associated with reduced muscle strength and mass. In a 
large study population of community-dwelling persons in Italy, a U-shaped 
relation was found between eGFR and physical performance in the oldest 
old group of persons ≥90 years.14 Subjects in the highest eGFR band had the 
lowest handgrip strength and ADL values comparable with subjects with the 
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lowest eGFR. In our study, a similar trend was found across a wider and also 
younger age range. However, due to the fact that slightly different methods 
were used in our study, the results cannot be fully compared to the study of 
Montesanto et al.
  There are several possible explanations for our results. In participants 
with higher eGFR, the observed smaller calf circumference and lesser 
handgrip strength, are likely manifestations of sarcopenia. Therefore, low 
s-creatinine resulting in high eGFR values might represent participants with 
less lean muscle mass and not necessarily with good filtration of s-creatinine 
in the kidney. Comparable results were also found using the CKD-EPI 
formula, although with less power most likely due to small shifts in numbers 
within eGFR categories. It should be noted that the MDRD-formula,23 like 
most other eGFR formulae,24 is validated in persons until the age of 70 years. 
Therefore, the MDRD-formula could be less reliable in older persons. This 
loss of reliability is the effect of changes in body composition with ageing, 
where, in general, muscle mass decreases.25 We did not find any relation 
between eGFR and mobility; this might be due to the fact that mobility, 
although dependent on muscle mass, is determined by many factors such 
as balance, reaction time, eyesight and pain,26,27 whereas handgrip strength 
and calf circumference are largely determined by muscle mass only.21,28 Since 
the highest eGFR values, i.e. low s-creatinine values, are associated with the 
lowest muscle mass and strength, the accuracy of estimating kidney function 
in older persons with formulae based on s-creatinine should be seriously 
questioned.
  The present study has several limitations. First, the cross-sectional 
design of the study limits the ability to draw conclusions about causality. 
Second, around 25 formulae are used for estimating GFR. We chose to use 
the MDRD and CKD-EPI-formula, the most used formulae nowadays.18,29 
It cannot be excluded that the use of another formula would have yielded 
(slightly) different results. Third, all participants attended the ED because of 
an accidental fall. Therefore, considering this characteristic, extrapolation 
to the general population is not possible. Our study also has strengths. 
First, we used data from a multicentre study, representing a heterogeneous 
group of older fallers throughout The Netherlands. Second, more than 500 
participants in a relatively wide range of age were included in analyses. Third, 
since s-creatinine based eGFR is the most common way to evaluate kidney 
function in clinical practice, showing the implications of using this eGFR in 
older fallers, makes our outcomes clinically relevant.
  In conclusion, we found that older fallers with a normal eGFR had 
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smaller calf circumference and up to 10% less handgrip strength than 
those with a reduced eGFR. This lower muscle mass is likely to lead to 
an overestimation of kidney function in such subjects. The findings of this 
study therefore support the current search for biomarkers independent of 
muscle mass to estimate kidney function in older persons. In clinical practice 
awareness of functional consequences of low s-creatinine and high eGFR 
values might be appropriate.
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Abstract
Purpose: Aortic stiffness (AS) is associated with cardiovascular events 
and all-cause mortality in the older population. AS might also influence the 
health-related quality of life (HRQOL) as a result of the negative effects of AS 
on cognitive and physical morbidity. We aimed to investigate the possible 
association between AS and HRQOL in people aged 75 years and over. 
Patients and Methods: This cross-sectional study was part of the 
SCOPE study, an international multicenter cohort observational study. 
The indicators for AS were aortic pulse wave velocity (aPWV) and central 
pulse pressure (cPP). HRQOL was assessed using the EQ-5D index 
and the EQ-5D visual analog scale (VAS). ANCOVA and multivariate 
regression models were used to investigate possible associations. 
Results: We included 280 Dutch participants of the SCOPE study. Median 
age was 79 years (IQR 76–83) and 42.1% were women. Participants reporting 
any problem on the EQ-5D index (n=214) had higher values of aPWV (12.6 vs 
12.2 m/s, p = 0.024) than participants not experiencing any problem (n=66) 
and comparable values of cPP (44.4 vs 42.0 mmHg, p = 0.119). Estimates 
only slightly changed after adjustments. No association was found between 
indicators of AS and EQ-5D VAS.
Conclusion: Aortic stiffness was associated with impaired quality of late 
life. This association could be mediated by subclinical vascular pathology 
affecting mental and physical health.
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Introduction
Aortic stiffness is a part of vascular aging,1-3 a phenomenon which can be 
accelerated by risk factors such as hypertension and diabetes mellitus.4-9 Aortic 
stiffness is a powerful predictor of cardiovascular events and all-cause 
mortality in several clinical populations as well as in community-dwelling 
older people.10-12 Aortic stiffness is also associated with microvascular brain 
disease,13,14 which can lead to decreased mental health in terms of cognition, 
mood, and daily functioning.15,16 As a result of these effects, aortic stiffness 
might also have a negative impact on quality of life. The negative impact 
of aortic stiffness on quality of life could be a subclinical result of vascular 
pathology or a result of the presence of comorbidities.17-20
  Previous studies have investigated the possible association between 
aortic stiffness and quality of life in several study populations.21-27 These 
studies show conflicting results. Moreover, to the best of our knowledge, 
no previous study has investigated the possible association between aortic 
stiffness and the quality of late life.
  Studying quality of life is relevant, since quality of life is a more 
powerful predictor of morbidity and mortality than many objective measures 
of health.28 Health-related quality of life (HRQOL) can be seen as a broad 
measure of health status and a supplement to traditional parameters as 
morbidity and mortality.
  The objective of this study was to determine whether there is an 
association between aortic stiffness and quality of life in older persons aged 
75 years and over.
Materials and Methods
Study Population
The Screening for Chronic kidney disease among Older People across 
Europe (SCOPE) study is a multicenter observational study with a prospective 
design in seven European countries.29 The primary objective of the study is to 
investigate the currently available screening methods to identify community-
dwelling older patients at risk of kidney disease. A detailed description of 
the study protocol can be found elsewhere.29 Patients with end-stage renal 
disease or dialysis, a history of solid organ or bone marrow transplantation, 
an active malignancy or metastatic cancer within 24 months prior to the visit, 
a life expectancy of less than 6 months, a severe cognitive impairment or 
patients unwilling to provide consent were ineligible for the SCOPE study. 
The current study population was a subset of the SCOPE study population 
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including only the Dutch participants (n=301). Data on aortic stiffness were 
only collected at participating centers in the Netherlands. The SCOPE 
study has been reviewed and approved by the Medical Ethics Committee 
of the Erasmus MC University Medical Center. This trial was conducted 
in accordance with the Declaration of Helsinki. This study was registered 
on the 25th February 2016 at clinicaltrials.gov, identifier NCT02691546. All 
participants provided written informed consent.
Study Visit
Baseline visit was scheduled at the Erasmus Medical Center Rotterdam or 
at the Havenziekenhuis Rotterdam. A comprehensive geriatric assessment 
was performed according to the SCOPE study protocol.29 The assessment 
included questionnaires, physical examination, and functional tests. Also, 
non-fastened blood and urine samples were taken.
Aortic Stiffness
Aortic stiffness was determined measuring aortic Pulse Wave Velocity 
(aPWV) with the Mobil-O-Graph (IEM, Rheinland, Germany), a previously 
validated oscillometric method.30 aPWV measurements were performed by 
a single measurement in resting sitting position using a brachial cuff. Other 
hemodynamic parameters that were obtained during the same measurement 
using inbuilt algorithms included blood pressure (both peripheral and central), 
mean arterial pressure (MAP), and heart rate (HR). In addition to aPWV, central 
pulse pressure (cPP) was also used as indicator of aortic stiffness.31,32 cPP 
was defined as the difference between central systolic blood pressure (SBP) 
and central diastolic blood pressure (DBP). The measurement was carried out 
in every participant. However, we excluded participants in which the device 
was not able to conduct a proper wave analysis due to technical issues.
Health-Related Quality of Life
The Euro QoL-5-dimensions (EQ-5D) questionnaire was used to measure 
HRQOL.33 The 5-level EQ-5D questionnaire has been validated in a variety 
of patient groups in six different countries, including the Netherlands.34 The 
questionnaire consists of two parts: a descriptive profile and a visual analogue 
scale (VAS). The descriptive part of the questionnaire provides information on 
the following five dimensions: mobility, self-care, daily activities, pain and 
discomfort, and anxiety and depression. A five-level Likert scale from no 
problems to being unable to function on the specific domain was used to 
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gather information about the specific domains. This information was then 
converted into a single index value that informs on the overall HRQOL.35 To 
calculate the EQ-5D index, a formula is used that weighs each dimension 
value with a tariff specific for the country at stake. The Dutch tariff was used 
in this study.36 The index value is depicted on a scale with 0 indicating death 
and 1 indicating full health. The EQ-5D VAS is a 20 cm scale from 0 to 100 in 
which respondents can fill out their current state of health. Zero equals the 
worst imaginable health status and 100 the best imaginable health status.
Statistical Analysis
Statistical analyses were performed using IBM SPSS Statistics version 24 for 
Windows. Participants with missing values for the aortic stiffness parameters 
were excluded. Descriptive statistics were expressed as percentage for 
categorical variables, mean and standard deviation (±SD) for continuous 
normally distributed variables, and median and interquartile ranges [IQR] for 
continuous non-normally distributed variables. Participants with an EQ-5D 
index value of 1 were classified as “no problem on any dimension” (group 
1), participants with an EQ-5D index value lower than 1 were classified as 
“any problem on the five dimensions” (group 2). First, characteristics were 
compared between these groups using the Mann–Whitney U-test and 
t-test for continuous variables. The Chi-square test was used to compare 
percentages. An analysis of covariance (ANCOVA) was used to investigate the 
possible association between aortic stiffness and the dichotomized version 
of EQ-5D index. Mean levels of aPWV and cPP were compared between 
these groups using two different models. Mean levels of pDBP and cDBP 
were also compared between these groups. We have identified potential 
covariates and included covariates with a p-value < 0.1 in the adjusted 
models when appropriate. Model 1 was adjusted for age, sex, mean arterial 
pressure and heart rate. Model 2 was additionally adjusted for Cumulative 
Illness Rating Scale (total score). A multivariable linear regression model was 
built to investigate the possible association between aortic stiffness (aPWV 
and cPP) and the EQ-5D VAS using the same models. A p-value of <0.05 was 
considered statistically significant.
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Results
Table 1. Participants’ characteristics 
Characteristics Total
No problem  
EQ-5D index  
(n=66)
Any problem  
EQ-5D index 
(n=214)
p-value
Age, years 79 [76-83] 78 [76-81] 79 [76-84] 0.047
Women, % 42.1 28.8 46.3 0.012
Education, years 12.1 (±4.5) 12.7 (±4.9) 11.9 (±4.4) 0.179
Packyears of smoking, 
years
5 [0-20] 3.9 [0-20] 6 [0-20.4] 0.528
Current smoker, % 5.0 3.0 5.6 0.824
Alcohol  ≥1 unit a day, % 34.3 39.4 32.7 0.317
BMI, kg/m² 26.3 (±4.3) 26.1 (±3.3) 26.3 (±4.5) 0.760
ADL dependent, % 15.4 9.1 17.3 0.106
iADL dependent, % 48.6 25.8 55.6 <0.001
MMSE, score 29 [27-30] 28 [27-30] 29 [27-30] 0.988
GDS, score 2 [1-3] 0 [0-1] 2 [1-4] <0.001
eGFR-BIS, mL/min 47.2 (±13.6) 46.6 (±13.1) 47.3 (±13.8) 0.701
Hypertension, % 70.7 62.1 73.4 0.079
Diabetes Mellitus, % 26.4 27.3 26.2 0.859
History of TIA/CVA, % 20.4 15.2 22.0 0.230
Atrial fibrillation, % 17.1 10.6 19.2 0.107
COPD, % 21.1 10.6 24.3 0.017
History of malignancy, % 23.6 15.2 26.2 0.065
CIRS, total score 12.8 (±4.9) 10.9 (±4.4) 13.4 (±4.9) <0.001
CIRS, severity index 1.8 (±0.3) 1.8 (±0.3) 1.9 (±0.3) 0.271 
Vascular parameters
pSBP, mmHg 146.1 (±20.2) 148.2 (±20.3) 145.4 (±20.1) 0.337
pDBP, mmHg 85.1 (±11.2) 88.4 (±11.8) 84.1 (±10.9) 0.006
MAP, mmHg 113.0 (±14.0) 115.8 (±14.8) 112.2 (±13.6) 0.068
pPP, mmHg 60.9 (±15.5) 59.7 (±13.8) 61.2 (±16.0) 0.509
Heart rate, bpm 69.8 (±12.2) 70.5 (±12.9) 69.5 (±11.9) 0.579
cSBP, mmHg 130.6 (±17.4) 132.2 (±16.6) 130.1 (±17.6) 0.395
cDBP, mmHg 86.7 (±11.3) 90.3 (±11.8) 85.7 (±11.0) 0.004
cPP, mmHg 43.8 (±12.8) 42.0 (±10.1) 44.4 (±13.5) 0.119
aPWV, m/s 12.5 (±1.2) 12.2 (±0.9) 12.6 (±1.3) 0.024
Notes: Continuous variables are presented as mean (±SD) or median [IQR]. P-values are based 
on T-test and Mann–Whitney U-Test for continuous variables and Chi-square test for categorical 
variables. Abbreviations: BMI, Body Mass Index; (i)ADL, (instrumental) Activities of Daily Living; 
MMSE, Mini–Mental State Examination; GDS, Geriatric Depression Scale; eGFR-BIS, estimated 
Glomerular Filtration Rate; TIA/CVA, transient ischemic attack/cerebrovascular accident; COPD, 
chronic obstructive pulmonary disease; CIRS, Cumulative Illness Rating Scale; pSBP, peripheral 
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systolic blood pressure; pDBP, peripheral diastolic blood pressure; MAP, mean arterial pressure; 
pPP, peripheral pulse pressure; cSBP, central systolic blood pressure; cDBP, central diastolic 
blood pressure; aPWV, aortic Pulse Wave Velocity; cPP, central Pulse Pressure. 
In total, 280 of the 301 Dutch participants were included in the study, 21 
participants were not included due to missing values of aortic stiffness. 
Characteristics are shown in Table 1. Median age was 79 years [IQR 76–83] 
and 42.1% were women. Few participants were ADL dependent (15.4%) 
and 48.6% of the participants were iADL dependent. Over 70% of the 280 
participants had hypertension, 26.4% diabetes mellitus, 23.6% a history 
of malignancy, 21.1% COPD, 20.4% a history of stroke and 17.1% atrial 
fibrillation. The mean score on the cumulative illness rating scale (CIRS) 
was 12.8±4.9 and the mean severity index of the CIRS was 1.8±0.3. The 
maximum value of 1 on the EQ-5D index (no problems) was scored by 66 
participants (23.6%). Participants reporting any problem on the EQ-5D index 
(76.4%) were older, more often women, more often iADL dependent, had 
higher scores on the geriatric depression scale and also higher comorbidity 
rates than those without problems on the EQ-5D index, which resulted in 
a higher CIRS total score (mean values 13.4±4.9 vs 10.9±4.4, p < 0.001). 
Characteristics stratified for problems on the EQ-5D index are also presented 
in Table 1.
  Participants with any problem on the EQ-5D index had lower 
peripheral (pDBP) and central DBP (cDBP) than participants without 
problems on the EQ-5D index. Mean values were 84.1±10.9 vs 88.4±11.8 
mmHg (p=0.006) and 85.7±11.0 vs 90.3±11.8 mmHg (p=0.004), respectively. 
Also, participants with any problem on the EQ-5D index had higher values 
of aPWV than participants without problems on the EQ-5D index (p=0.024). 
Mean values were 12.6±1.3 and 12.2±0.9 m/s, respectively.
  Table 2 shows the characteristics of the EQ-5D outcome measures. 
Median EQ-5D index was 0.86 [IQR 0.81–0.91] and the mean EQ-5D VAS was 
74.9±14.8. No problems were reported by 42.5% of participants on mobility, 
92.5% on self-care, 78.9% on daily activities, 44.6% on pain and discomfort, 
and 83.6% on anxiety and depression.
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Table 2. Characteristics of health-related quality of life (n=280)
Characteristics
EQ-5D index, score 0.86 [0.81-0.91]
EQ-5D VAS, score 74.9 (±14.8)
No problems per dimension
Mobility, % 42.5
Self-care, % 92.5
Daily activities, % 78.9
Pain/discomfort, % 44.6
Anxiety/depression, % 83.6
Notes: Continuous variables are presented as mean (±SD) or median [IQR]. Abbreviations: EQ-
5D VAS, EQ-5D Visual Analogue Scale
Figure 1 shows the mean levels of aortic stiffness according to EQ-5D index 
status (no problem vs any problem). The mean values of aPWV were higher 
in the any problem group than in the no problem group (12.52 m/s vs 12.39 
m/s, p = 0.024). In model 2, the mean aPWV values remained unchanged with 
a 0.12 m/s higher mean aPWV in the group with any problem (p = 0.041). The 
mean values of cPP were 3.3 mmHg higher in the any problem group than in 
the no problem group (44.6 mmHg vs 41.3 mmHg, p = 0.042). This difference 
persisted in model 2 (44.6 mm Hg vs 41.2 mmHg, p = 0.041).
  Mean levels of pDBP and cDBP were also compared between the 
two groups (no problem vs any problem). However, in multivariate analysis 
in both model 1 and model 2, mean values did not differ between groups 
(data not shown). A trend was observed between aPWV and EQ-5D VAS 
in model 1. Per m/s increase in aPWV, the EQ-5D VAS score changed with 
−4.15 (95% CI −8.71–0.42), whereas no association was found in model 2. 
No association was found between cPP and the EQ-5D VAS. In model 1, B 
coefficient and 95% CI for cPP were −0.05 (−0.21–0.11); Estimates in model 
2 were only slightly changed.
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Figure 1. Mean values of aortic stiffness according to EQ-5D index status 
(n=280)
 
Notes: Figure 1A and 1B: aortic Pulse Wave Velocity (aPWV) in m/s; Figure 1C and 1D: central 
Pulse Pressure (cPP) in mmHg. Model 1: adjusted for age, sex, mean arterial pressure and heart 
rate; Model 2: additionally adjusted for Cumulative Illness Rating Scale total score. Dots represent 
mean values, bars represent 95% confidence intervals.
Discussion
In this exploratory study, we found that aortic stiffness, assessed as aortic 
pulse wave velocity and central pulse pressure, was associated with an 
impaired quality of life in people of 75 years and over. This association in late 
life was independent of age, blood pressure levels, and comorbidities.
  Several mechanisms might explain our results. First, the association 
between aortic stiffness and quality of late life could be mediated by 
impaired physical health. Aortic stiffness is known to play an important 
role in the development and progression of diseases in end-organs and 
the presence of these diseases could affect the quality of life.37 However, 
the association between aortic stiffness and quality of life persisted even 
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after adjustment for cumulative comorbidities suggesting an independent 
role of aortic stiffness. Second, impaired mental health could also 
mediate the association between aortic stiffness and quality of life. 
Elevated aortic stiffness can lead to cerebral small vessel disease, which 
is associated with cognitive decline as well as mood disturbances.15,38-40 
It is very well possible that quality of life questionnaires might be able to 
detect vascular pathology already in a subclinical stage. Subclinical vascular 
damage could be already revealed in measures of quality of life before it 
results in multiple physical and mental comorbidities. An increase in aPWV of 
1 m/s amplifies the risk of cardiovascular morbidity and mortality as well as 
all-cause mortality by 15%.10 In this study, we found 0.12 m/s higher aPWV 
and 3.4 mmHg higher cPP in participants with poorer quality of life indexes. 
Although an increase in aPWV of 0.12 m/s or 3.4 mmHg higher cPP may 
seem relatively modest and the effect size is small, these differences could 
already have an impact on daily functioning, both physically and mentally. 
Therefore, aortic stiffness might be a tissue biomarker reflecting the vitality 
status of the single individual. In addition, aortic stiffness determines high 
mean SBP levels and low DBP levels, and consequently a wide pulse 
pressure.41 It can be speculated that aortic stiffness together with consequent 
aberrant hemodynamic changes can affect quality of life by determining 
cardiovascular morbidity. It cannot be excluded that lower quality of life may 
also have an effect on aortic stiffness. It has been suggested that lower quality 
of life also represents people with lower social support or more depressive 
symptoms.42,43 As result of this, it could be hypothesized that lower quality 
of life might also affect (hypertension) treatment compliance and therefore 
deterioration of health which negatively affects the function of the arteries. In 
addition, lower mobility and the presence of depressive symptoms and pain 
may also perpetuate a physically inactive lifestyle, which is associated with a 
change in vascular function and increase in stiffness.44
  We found a discrepancy in the results of the EQ-5D index and the EQ-
VAS. This discrepancy could be explained by the nature of the questionnaires. 
Noticing and reporting actual disabilities in daily life in the EQ-5D index does 
not necessarily mean that the self-perceived health on the EQ-VAS is scored 
as worse. Namely since in the EQ-VAS, an individual values his or her health 
position in life in the context of cultural and social aspects. In other words, 
these two questionnaires score different aspects of quality of life. Another 
well-known problem with the EQ-VAS is the end-of-scale bias which results 
in small numbers of extreme values, which could make the EQ-VAS less 
reliable than the EQ-5D index.
  Some aspects of this study need further consideration. First, the 
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cross-sectional study design does not allow to draw causal inferences. 
Second, the sample size was relatively small and the population consisted of 
outpatient older persons. This could affect the power to investigate possible 
associations between aortic stiffness and quality of life. However, despite the 
limited number of participants and the possible selection bias, we were able to 
detect significant differences with a small effect size between those with and 
without problems in quality of life. The difference in cPP reached statistical 
significance in adjusted models, which might suggest that this result is due 
to chance or that the sample size for this specific analysis is underpowered. 
In a larger and more heterogeneous population, these differences might be 
amplified. Third, we measured aortic stiffness with an oscillometric method. 
This method is validated and gives reliable results when compared to 
invasive measurements,30 however, the predictive value of this measurement 
to cardiovascular outcomes has not been investigated. One of the strengths 
of this study is the fact that we categorized EQ-5D index into no problem and 
any problem. The splitting partly resolved the problem of skewed values, but 
this made the results also more relevant in clinical practice. Another strength 
is the use of several markers of aortic stiffness such as aPWV and cPP. These 
central measures play a fundamental role in end organ disease and are 
therefore accurate and clinically relevant markers.32,37 
 The association between aortic stiffness and quality of life has been 
investigated before. Nevertheless, most previous studies did not observe 
an effect on overall HRQOL but only on the physical component of 
the HRQOL.21,23,24,27 Only one study has described an effect on overall 
HRQOL.25 However, this study was performed in a very small sample of 56 
patients undergoing surgical aortic valve replacement. Our study sample 
differed from previous studies, since we have focussed on a specific 
population of older patients in late life, whereas the previous studies have 
focussed on younger patients or specific patient categories.
Conclusion
In conclusion, aortic stiffness was associated with impaired quality of life in 
people of 75 years and over. This association in late life was independent 
of age and other cardiovascular risk factors and might be mediated by 
subclinical vascular pathology affecting mental and physical health. Future 
research is required to establish whether aortic stiffness has a predictive 
value for a deterioration in quality of life.
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Abstract
Purpose: Cerebral white matter lesions (WML) and brain atrophy are 
frequent in older persons and are associated with adverse outcomes. It 
has been suggested that aortic stiffness plays a role in the pathogenesis 
of WML and gray matter (GM) loss. There is, however, little evidence on the 
association between aortic stiffness and brain integrity in older patients. In 
this study, we investigated whether aortic stiffness is associated with WML 
and GM volume in older patients with cognitive and functional complaints. 
 
Patients and methods: Fazekas score was used to analyze WML on brain 
imaging data of 84 persons; in a subanalysis on 42 MRI scans, the exact 
volume of white matter hyperintensities (WMH) and GM was determined 
using a brain-tissue and WMH tool. Aortic stiffness, measured as aortic 
pulse wave velocity (aPWV) and central pulse pressure (cPP), and blood 
pressure levels were non-invasively measured by the Mobil-O-Graph. 
 
Results: Mean age was 76.6 (±6.8) years. Age was correlated with cPP 
(Spearman’s ρ =0.296, P=0.008), aPWV (r2=0.785, P<0.001) and WMH 
volume (r2=0.297, P<0.001). cPP did not differ between categories of 
Fazekas, whereas aPWV increased with increasing Fazekas score (P for 
trend <0.001). After additional adjustment for age, levels of aPWV did 
not differ between categories. Both cPP and aPWV were associated with 
WMH volumes (lnB 0.025, P=0.055 and lnB 0.405, P<0.001, respectively); 
after additional adjustment for age, estimates were less consistent. 
Both cPP and aPWV were negatively associated with GM volumes in 
multivariate analysis (B=2.805, P=0.094 and B=111.052, P=0.032). 
 
Conclusion: Higher aortic stiffness was partly associated with increased 
volume of WMH and decreased volume of GM and slightly influenced by 
blood pressure. Age also plays a role in this association in older patients.
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Introduction
Cerebral white matter lesions (WML) and gray matter (GM) volume loss are 
frequently seen in older persons.1,2 These age-related processes can be 
associated not only with gait disturbances and mood disorder but also with 
cognitive and functional decline and mortality.3-8 Known risk factors for brain 
abnormalities are hypertension, diabetes mellitus, and inflammation.9-12 Also 
genetic predisposition, such as Anderson–Fabry disease, can result in 
WML.13,14 It has been suggested that arterial stiffness also plays a role in the 
pathogenesis of WML.15 
  Increased arterial stiffness leads to an increased pulsatile pressure, 
which can affect the microcirculation in high-flow organs leading to cerebral 
small vessel disease (CSVD).15,16 A recent systematic review and meta-
analysis was conducted on the association between arterial stiffness and 
CSVD.17 Most studies included in the systematic review found an independent 
association between arterial stiffness and different markers of CSVD.18-
27 However, most of these studies investigated the effect of arterial stiffness 
on cerebral infarcts or cerebral microbleeds and not on WML.20-22,24,25,27 
Several studies used brachial-ankle pulse wave velocity (PWV) instead of 
more reliable central measurements (ie, aortic stiffness) or included specific 
categories of patients at risk for cardiovascular disease.18,20-23,25,26 There is, 
however, little evidence on the possible association between aortic stiffness 
and WML in the older patient. Also, little is known on the association between 
arterial stiffness and GM volume, which has only been investigated in young 
adults and selected groups of patients.28-31 No previous study has investigated 
the possible association between aortic stiffness and GM volume in older 
persons. 
 The aim of this study was to investigate the relationship between 
measures of aortic stiffness and both GM volume and the severity of cerebral 
WML load in a population of elderly patients with cognitive and functional 
complaints.
Materials and methods
From April 2015 to June 2016, all patients entering the outpatient clinic of 
geriatrics of the Erasmus MC, University Medical Center Rotterdam, were 
asked to participate in the study. Patients with (reliable) measurements of aortic 
stiffness and brain imaging were included. MRI and computed tomography 
(CT) scans were used for analysis when brain imaging was performed within 
6 months before or after the study visit. The ethical committee of the hospital 
approved this study and all participants signed informed consent. During 
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the study visit, biographical information was collected and measurements 
of aortic stiffness were obtained. Medical history, medication, and lifestyle 
factors were documented. Height and weight were measured, and body mass 
index was calculated as kg/m2. Global cognitive function was assessed with 
the Mini Mental State Examination score.32 Katz index and Lawton and Brody 
index were used for scoring activities of daily living (ADL) and instrumental 
ADL, respectively.33,34 Instrumental ADL dependency was defined as ≥1 
limited activity.
Vascular measurements
Aortic stiffness was non-invasively measured with a validated method by 
the Mobil-O-Graph (Mobil-O-Graph 24 hours PWA Monitor; I.E.M. GmbH, 
Stolberg, Germany).35,36 Central and peripheral systolic blood pressure (SBP), 
diastolic blood pressure (DBP), and pulse pressure (PP) were also measured. 
Aortic pulse wave velocity (aPWV) and central pulse pressure (cPP) were used 
to reflect aortic stiffness.35,37 Mean arterial pressure (MAP) was calculated as 
DBP +1/3 (SBP–DBP).
Brain imaging
Brain imaging was performed as part of clinical work-up of patients with 
cognitive and/or functional complaints. The Fazekas scale was used by 
one experienced radiologist to score the severity of WML on MRI and CT 
scans.38 The Fazekas scale represents the sum of deep white matter corps 
and periventricular corps divided into three categories of increasing severity 
(0= absent, 1= punctuate foci, 2= beginning confluence of foci, and 3= large 
confluent area). For more quantitative estimates, the brain tissue and white 
matter hyperintensity (WMH) segmentation tool, as developed by Quantib B.V. 
(www.quantib.com), was applied to T1-weighted and FLAIR scans. This tool 
generates automatic segmentations of GM, white matter (WM), cerebrospinal 
fluid and WMH in the cerebrum.39 The algorithm used is available for clinical 
use in the Quantib Brain product (v1.2) and an improved version is available 
in Quantib ND (v1.5). From these segmentations, we computed volumes in 
milliliters of total GM and WMH.
Statistical analyses
All analyses were performed using SPSS statistics 24. Descriptive data for 
continuous variables were presented as mean ± SD or median and IQR. 
Number and percent prevalences were presented for dichotomous variables. 
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Data of variables with a skewed distribution (WMH in mm³ and cPP) were 
log-transformed using the natural logarithm. Spearman’s correlation analysis 
was used to investigate the relationship between age and cPP. Pearson’s 
correlation analysis was performed to investigate the relationship between 
age (independent variable) and aPWV, the natural logarithm of WMH volume, 
and GM volume (dependent variables). In analysis of covariance (ANCOVA), 
mean cPP and aPWV were investigated across categories of Fazekas score 
in three different models: model A was unadjusted; model B was adjusted 
for MAP; model C was adjusted for MAP and age. Mean values of cPP were 
back transformed to original scale. The significant associations in ANCOVA 
analysis were reevaluated using the Bonferroni method for multiple testing 
(P<0.0083). Linear regression analysis was performed to assess whether cPP 
and aPWV (determinant) were associated with WMH and GM volume, as a 
continuous variable (outcome). The same models as in the ANCOVA analyses 
were used. All tests were two-sided and a P-value <0.05 was considered as 
statistically significant.
Results
In total, 250 patients signed informed consent. A total of 166 patients had no 
reliable measurements of aPWV and/or brain imaging available. Therefore, 
the study population consisted of 84 patients. The characteristics of the 
population are shown in Table 1. Mean age was 76.6±6.8 years, 65.5% 
were men, and 65.5% lived with a partner. Most of the patients were ADL 
independent (65.5%) and 26.2% were iADL independent.
   Median peripheral SBP was 138.0 mmHg [IQR 124.0–148.0] and 
DBP was 83.5 mmHg [IQR 77.0–93.0]. Median central SBP was 125.5 mmHg 
[IQR 114.3–136.0] and DBP was 85.0 mmHg [IQR 78.0–94.5]. Median cPP 
was 37.5 mmHg [IQR 31.0–45.8]. Mean aPWV was 11.6±1.65 m/s. Fourteen 
percent of the patients were classified as Fazekas 0, 23.8% as Fazekas 1, 
17.9% as Fazekas 2, and 44.0% as Fazekas 3. Median volume of WMH was 
3.1 mL [IQR 0.8–6.4]. Mean GM volume was 679.5±130.7 mL.
  Age was associated with cPP (Spearman’s r=0.296, P=0.008), aPWV 
(Pearson’s r=0.886, P,0.001), and WMH volume (Pearson’s r=0.545, P,0.001), 
but not with GM volume (Pearson’s r=-0.179, P=0.255). Results are shown in 
Figure 1. 
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Table 1. Characteristics of the study population (n=84) 
Age in years, mean (± SD)
Men, n (%)
Living alone, n (%)
Living with partner, n (%)
Current smoker, n (%)
Ex-smoker, n (%)
ADL independent, n (%)
iADL independent, n (%)
MMSE score, median [IQR] 
Hypertension, n (%)
Diabetes mellitus, n (%)
Peripheral hemodynamics
pSBP in mmHg, median [IQR] 
pDBP in mmHg, median [IQR]
pPP in mmHg, median [IQR] 
Central hemodynamics
cSBP in mmHg, median [IQR]
cDBP in mmHg, median [IQR]
cPP in mmHg, median [IQR]
aPWV in m/s, mean (± SD)
Brain integrity
Fazekas category 0, n (%)
Fazekas category 1, n (%)
Fazekas category 2, n (%)
Fazekas category 3, n (%)
WMH in ml, median [IQR]a 
Gray matter in ml, mean (± SD)a
76.4 (± 7.0)
55 (65.5)
29 (34.5)
55 (65.5)
11 (13.1)
44 (52.4)
55 (65.5)
22 (26.2)
25.5 [23 – 28]
37 (44.0)
24 (28.6) 
138.0 [124.0 – 148.0]
83.5 [77.0 – 93.0]
50.0 [42.5 – 63.8] 
 
125.5 [114.3 – 136.0]
85.0 [78.0 – 94.5]
37.5 [31.0 – 45.8]
11.6 (± 1.65)
12 (14.3)
20 (23.8)
15 (17.9)
37 (44.0)
3.1 [0.8 – 6.4]
679.5 (± 130.7)
Note: aData on WMHand gray matter were available for 42 patients. Abbreviations: ADL, 
activities of daily living; iADL, instrumental activities of daily living; pSBP, peripheral systolic 
blood pressure; pDBP, peripheral diastolic blood pressure; pPP, peripheral pulse pressure; 
cSBP, central systolic blood pressure; cDBP, central diastolic blood pressure; cPP, central pulse 
pressure; aPWV, aortic pulse wave velocity; WMH, white matter hyperintensity.
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Figure 1. Association between age and measures of aortic stiffness and brain 
integrity
 
Notes: (A) Central pulse pressure (cPP); (B) aortic pulse wave velocity (aPWV); (C) natural 
logarithm of white matter hyperintensities (log-WMH); and (D) gray matter (GM). 
Figure 2 shows the mean values and 95% CI of cPP and aPWV across Fazekas 
categories. No differences were found in mean cPP values across categories 
of Fazekas in unadjusted analysis (Figure 2A). Mean values and 95% CI were 
35.3 (29.2–42.7) mmHg, 36.2 (31.2–41.9) mmHg, 35.2 (29.7–41.7) mmHg, 
and 42.4 (37.8–47.5) mmHg from lowest to highest Fazekas categories, 
respectively. Mean values of cPP in model B slightly differed from univariate 
analysis (Figure 2B). Mean values and 95% CI were 37.6 (31.4–44.9) mmHg, 
36.3 (31.7–41.6) mmHg, 36.3 (31.0–42.6) mmHg, and 40.7 (36.6–45.4) mmHg 
from lowest to highest Fazekas categories, respectively. In model C, no 
differences were found in mean values of cPP across categories of Fazekas 
(Figure 2C). Mean values and 95% CI were 39.5 (32.8–47.5) mmHg, 37.6 
(32.7–43.2) mmHg, 36.2 (31.0–42.3) mmHg, and 39.2 (35.0–44.0) mmHg from 
lowest to highest Fazekas categories, respectively.
 Mean values of aPWV increased from lowest to highest categories of 
Fazekas (test for trend P,0.001) in unadjusted analysis (Figure 2D). Mean values 
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and 95% CI were 10.4 (9.6–11.2) m/s, 10.9 (10.3–11.5) m/s, 11.5 (10.7–12.2) 
m/s, and 12.6 (12.1–13.1) m/s, respectively. A significant difference in aPWV 
was found between categories 0 and 3 (mean difference 2.2 m/s, P,0.001) 
and 1 and 3 (mean difference 1.7 m/s, P,0.001). In model B, aPWV was higher 
in those in Fazekas 3 than those in Fazekas 0 (mean difference 1.8 m/s, 
P,0.001) and in Fazekas 1 (mean difference 1.5 m/s, P,0.001). Furthermore, 
aPWV increased from lowest to highest categories of Fazekas (test for trend 
P,0.001) comparable with unadjusted analysis (Figure 2E). Mean values and 
95% CI of aPWV from lowest to highest categories were 10.7 (9.9–11.4) 
m/s, 10.9 (10.3–11.5) m/s, 11.6 (10.9–12.3) m/s, and 12.4 (12.0–12.9) m/s, 
respectively. In model C, aPWV did no longer differ between categories of 
Fazekas. Mean values and 95% CI of aPWV were 11.7 (11.4–11.9) m/s, 11.6 
(11.4–11.8) m/s, 11.5 (11.3–11.7) m/s, and 11.7 (11.5–11.8) m/s from lowest 
to highest Fazekas categories, respectively (Figure 2F).
  Levels of cPP showed a trend toward linear association with (natural 
logarithm of) WMH (lnB =0.025, 95% CI −0.001; 0.052) and this trend only 
slightly changed in model B (lnB =0.027, 95% CI −0.001; 0.056). Nonetheless, in 
model C, no association was found between cPP and WMH (lnB =0.014, 95% 
CI −0.013; 0.040) (Table 2). Levels of aPWV were linearly associated with (natural 
logarithm of) WMH (lnB =0.405, 95% CI 0.204; 0.606) and remained significant in 
model B (lnB =0.449, 95% CI 0.233; 0.664). In model C, however, no association 
was found between aPWV and WMH (lnB =0.382, 95% CI -0.436; 1.201). Levels 
of cPP were negatively associated with GM volume in univariate analysis (B=-
2.952, 95% CI -5.818; -0.086). In models B and C, a negative trend toward 
association was found between cPP and WMH (B=-3.080, 95% CI -6.207; 
0.046; B=-2.805, 95% CI -6.111; 0.501, respectively). A negative trend was also 
found between aPWV and GM volume in univariate analysis (B=-22.235, 95% CI 
-47.653; 3.183). In model B, estimates were slightly less consistent (B=-22.766, 
95% CI -50.495; 4.963). In model C, a negative association was found between 
aPWV and GM volume (B=-111.052, 95% CI -211.840; -10.265).
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Figure 2. Mean values of aortic stiffness across categories of Fazekas scores 
Notes: (A–C) Central pulse pressure (cPP); (D–F) aortic pulse wave velocity (aPWV). Model A, 
unadjusted; model B, adjusted for mean arterial pressure; model C, adjusted for mean arterial 
pressure and age. P-value <0.05/6 is statistically significant (Bonferroni correction). Dots 
represent mean values and bars represent 95% CI. 
Table 2. Linear regression coefficients describing the associations between 
measures of aortic stiffness and brain integrity (n=42)
WMH volume in mm³  
lnB (95% CI)
GM volume in mL  
B (95% CI)
cPP (mmHg)
Model A
Model B
Model C 
aPWV (m/s)
Model A
Model B
Model C
 
0.025 (−0.001; 0.052)
0.027 (−0.001; 0.056)
0.014 (−0.013; 0.040) 
0.405 (0.204; 0.606)
0.449 (0.233; 0.664)
0.382 (−0.436; 1.201)
 
−2.952 (−5.818; −0.086)
−3.080 (−6.207; 0.046)
−2.805 (−6.111; 0.501) 
−22.235 (−47.653; 3.183)
−22.766 (−50.495; 4.963)
−111.052 (−211.840; −10.265)
Notes: Model A, unadjusted; model B, adjusted for mean arterial pressure; model C, adjusted 
for mean arterial pressure and age.Abbreviations: WMH, white matter hyperintensity; GM, gray 
matter; cPP, central pulse pressure; aPWV, aortic pulse wave velocity
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Discussion
In this study, we found that higher aortic stiffness was partly associated with a 
higher load of cerebral WML and lower GM volume in patients with cognitive 
and functional complaints. This association was slightly influenced by blood 
pressure. Higher aortic stiffness was found to be associated with a higher 
Fazekas score. The association was strongly mediated by age.
  In a community-based cohort of 668 participants who were between 
the age of 69 and 93, higher levels of carotid-femoral pulse wave velocity 
were associated with diffuse microvascular brain lesions, which included 
subcortical infarcts and higher volumes of WMH.24 Carotid pulse pressure 
was associated with increased risk of silent subcortical infarcts. However, this 
study was performed in an apparently healthy population of older individuals, 
and those with a history of stroke, transient ischemic attack, or dementia were 
excluded. Considering these differences in the inclusion, the results of the 
two studies are not completely comparable. Also, previous studies were most 
often performed in specific categories of patients such as young hypertensives 
and diabetics.18,23 In these populations, higher aortic stiffness was associated 
with a greater volume of WMH. In addition, Saji et al found that increased 
brachial-ankle PWV was associated with WML in healthy adults in Japan.40 
Since brachial-ankle PWV is not a measure of aortic stiffness, these results 
could not be compared with our findings. A recent systematic review made 
an overview of all studies investigating the association between arterial 
stiffness and CSVD, summing up the results in diverse study populations 
using diverse methods of defining arterial stiffness and CSVD.17 Out of the 
15 cross-sectional studies included, 73% showed an association between 
greater arterial stiffness and CSVD.17 
  A few studies found an inverse relation between aortic stiffness and 
GM volume.28-30 However, these studies were conducted in young and healthy 
adults, in type 2 diabetics, and in patients with manifest arterial disease. 
No previous study has investigated the potential role of aortic stiffness in 
determining brain integrity in older persons with cognitive and functional 
complaints.
  The mechanisms underlying the association between aortic stiffness 
and CSVD have previously been described as when aortic stiffness increases 
the pulsatile pressure.15,16 High pulsatile pressure increases the flow load 
and can cause damage in high-flow organs. This damage can be seen as 
WML, but also as cerebral microbleeds and lacunar infarcts, which are all 
markers of CSVD. The high pressure can affect the brain directly resulting in 
microvascular damage. Besides the direct damage that increased flow load 
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can cause, it may also induce an indirect remodeling response by elevating the 
vascular resistance to protect the microvascular system from high pressures. 
This response might lead to ischemia in the long term.17 Moreover, GM 
atrophy may be the result of damages to the small cerebral arteries caused by 
vascular disease in advanced stage.28 The role of age in vascular processes 
is attributed to degenerative changes. At a molecular level, vascular aging is 
characterized by breaks in elastin fibers, accumulation of collagen, fibrosis, 
inflammation, and calcifications. All these processes result in a decline of 
the elastic properties of the central large arteries.41 Also cardiovascular 
diseases contribute to the decline of these elastic properties due to vascular 
remodeling.9 Interestingly, in this study population, the majority have had or 
still had cardiovascular diseases. However, the role of age still seems to be 
very important. We cannot exclude that associations between aortic stiffness 
and brain integrity would be different in a study population with a wider range 
of age and therefore a different time of exposure to risk factors. Moreover, 
we are aware that participants of the present study have an elevated load of 
degenerative vascular alterations due to age and comorbidities and possibly 
patients with elevated vascular stiffness might not be included in the study 
due to morbidity or mortality.
  This study has some limitations. First, the cross-sectional study 
design did not allow us to draw conclusions about causality. Second, the 
low number of available MRI scans can limit the possibility to add further 
adjustments in analysis on WMH and GM. Third, we included older patients 
within a relatively small range of age and with an elevated load of degenerative 
vascular alterations. These “ceiling effects” in a relatively small sample of 
elderly could limit the ability to assess the role of aortic stiffness in brain 
integrity.
  This study also has strengths. First, we used both graded scores 
(Fazekas) and more quantitative and automatic methods for assessing 
the cerebral WML load in order to investigate the association between 
aortic stiffness and WML. Moreover, the Fazekas score was scored by one 
experienced radiologist, which makes the results less susceptible to variability 
as a result of different raters. Second, we used two parameters of central arterial 
stiffness. cPP and aPWV both reflect aortic stiffness.35,37  Aortic stiffness is 
known to play a fundamental role in the development and progression of 
disease in end organs.42 Thus, the use of aortic stiffness as a parameter to 
assess brain integrity makes the outcomes of this study clinically relevant.
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Conclusion
We found that higher levels of aortic stiffness were partly associated with 
increased cerebral WML load and decreased GM volume in elderly patients 
with cognitive and functional complaints. This association seems to be slightly 
influenced by blood pressure and strongly driven by age. In this population 
of older patients, majority of whom were exposed to cardiovascular disease, 
age is still an important factor, most likely due to a cumulative exposure to risk 
factors and age-related degenerative processes. Prospective investigations in 
a larger geriatric population are recommended to investigate the independent 
role of aortic stiffness in the development and progression of WML and loss 
of GM over time.
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Blood pressure (dys)regulation and falls 
6.1
Orthostatic hypotension, 
fear of falling and physical 
performance in older adults
L. Tap, N. Boyé, K. Hartholt, N. van der Velde, T. van der Cammen, 
F. Mattace-Raso 
 
Orthostatic drop in diastolic but not systolic blood pressure 
is associated with fear of falling in older fallers 
 
Adapted from: Journal of the American Medical Directors Association, 
Mar. 2020
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Abstract
Objectives: Orthostatic hypotension (OH) is frequent in older persons 
and associated with adverse outcomes. We investigated associations 
between OH, fear of falling and physical performance in older fallers. 
Design: Cross-sectional study.
 
Setting and Participants: 523 participants of the IMPROveFALL study, 
aged ≥ 65 years who had visited the emergency department due to a fall. 
 
Methods: OH was defined as a decline of ≥20mmHg systolic (SBP) 
or ≥10mmHg diastolic blood pressure (DBP) within 5 minutes of 
standing. Mobility was tested with the Timed-Up-and-Go-test (TUG) 
and Five-Times-Sit-to-Stand-test (FTSS), balance with the tandem 
test. ADL and iADL dependency and use of a walking aid were scored. 
Participants were classified as having fear/no fear of falling. Associations 
were investigated using ANCOVA and logistic regression models. 
Results: In total, 49.7% had OH and median age was 76.2 years. Mean 
time to complete the TUG did not differ between fallers with and without 
OH, mean time was 10.6 seconds (95% CI 9.9-11.2) and 10.8 (95% CI 10.2-
11.5), respectively. Mean time to complete the FTSS in both groups was 16.2 
seconds (95% CI 15.4-17.1). No association was found between OH and 
balance, (i)ADL dependency or use of a walking aid. OR for fear of falling was 
1.45 (95% CI 1.01-2.09) for older fallers with OH. Highest ORs were found 
in the groups with the greatest drop of DBP up to 4.22 (95% CI 1.89-9.45). 
Conclusions and implications: Fear of falling is more frequent in older 
fallers with OH and especially in those with a greater drop in DBP. Low DBP 
is associated with low coronary supply and possibly an impaired organ 
perfusion. The present findings can help to understand the mechanisms 
underlying a multifactorial problem: falls.
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Introduction
Orthostatic hypotension (OH) is very common in older persons and associated 
with several adverse outcomes,1 such as syncope, cardiovascular morbidity 
and mortality.2-4 Moreover, since OH can cause symptoms of dizziness and 
instability, it can also lead to falls and bone fractures5. Consequences of falls 
are known to contribute to physical impairment and decreased quality of 
life.6,7 It is estimated that up to 10% of falls occur secondary to abnormal 
blood pressure responses such as OH.5 However, it is not completely clear 
whether older fallers with OH differ from older fallers without OH in terms of 
their physical performance. 
  A recent systematic review and meta-analysis in older adults 
showed that OH was associated with objective or self-reported impaired 
balance and lower ADL performance.8 No association was found with 
other physical functioning categories such as gait characteristics and 
mobility. All analyses in this study were stratified for different populations 
of older adults, such as community dwelling older persons, outpatients, 
inpatients, nursing home residents or patients with parkinsonism. However, 
no previous study has investigated the possible association between 
OH and physical performance in older fallers. The aim of this study was 
to investigate the possible association between OH and objective and 
self-reported physical performance in older persons who have fallen. 
 
Methods
Baseline data from the Improving Medication Prescribing to reduce Risk Of 
FALLs (IMPROveFALL) study were analyzed. The IMPROveFALL-study is a 
randomized multicenter trial investigating the effect of withdrawal of fall-risk 
increasing drugs versus ‘care as usual’ on reducing falls in community-dwelling 
persons. A detailed description of the methods can be found elsewhere.9 In 
summary, individuals aged ≥65 years who visited the Emergency Department 
(ED) because of a fall were asked to participate. Individuals had a Mini-
Mental State Examination (MMSE) score of at least 21 out of 30 points.10 
The baseline visit took place within two months after ED attendance. 
The ethical committee of the Erasmus MC University Medical Center 
Rotterdam approved the study and all participants signed informed consent. 
 
Orthostatic hypotension
OH was measured with a calibrated sphygmomanometer, in supine position 
followed by five minutes standing. Blood pressure was measured in supine 
position and after one, two, three, four, and five minutes standing. Systolic 
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(SBP) and diastolic blood pressure (DBP) was registered in millimeters of 
mercury (mmHg), heart rate in beats per minute (bpm). OH was defined as 
a drop in SBP of at least 20 mmHg or DBP of at least 10 mmHg within the 
5 minutes in standing position.11 Participants not completing the orthostatic 
challenge without the occurrence of OH were excluded from analyses, since no 
conclusion can be drawn about the presence of OH within those five minutes. 
 
Physical performance
In order to assess physical performance, multiple performance tests were 
conducted. 
 
Dynamic physical performance: mobility tests
In the Timed-Up-and-Go test (TUG), the participant has to stand up from 
sitting position and walk three meters along a line, perform a 180 degree 
turn and walk back to the chair and sit down.12 The Five-Time-Sit-to-Stand 
test (FTSS) is a standardized test in which the participant stands up and sits 
down five consecutive times.13 Both mobility tests were conducted twice, 
and the best time was used. If participants were not able to perform the 
TUG and/or FTSS, participants were only excluded from related analysis. 
 
Static physical performance: balance test
A tandem stand test was used in order to assess balance.13 The test is 
performed in standing position, in which the participant has to stand fully 
independently for 10 seconds with both feet in front of each other. The test is 
scored as correct or failed.
 
Functional (in)dependency
Katz index and Lawton and Brody index were used for scoring activities 
of daily living (ADL) and instrumental ADL, respectively.14,15 The ADL scale 
assesses six functions: bathing, dressing, toileting, transferring, continence 
and eating.14 The iADL scale assesses seven functions: use of telephone, 
transportation, preparation of a meal, household, shopping for groceries, 
taking medications and managing money.15 Fully independent was defined 
as a score of zero, whereas (i)ADL-dependency was defined as having ≥1 
limited activity. To determine functional dependency, it was documented 
whether or not a walking aid was used in daily activities.  
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Fear of falling
The Falls Efficacy Scale (FES) was used to assess fear of falling.16 Each 
participant was asked to report how concerned about falling he/she felt while 
carrying out each of ten activities of daily living. Answers on each item were 
rated on a 4-point scale (0 = not concerned, 3 = very concerned). Fear of 
falling was present when the FES score was ≥1. Fear of falling can be seen as 
an indicator of physical performance, since fear of falling is associated with 
limitations in mobility.17,18
 
Statistical analysis
All analyses were performed using SPSS statistics 24. Descriptive data for 
continuous variables were presented as median and interquartile range (IQR). 
Percent prevalences were presented for dichotomous variables. Descriptive 
statistics were compared between participants with and without OH. A Mann 
Witney U test was performed for continuous variables, a Chi-square test was 
used to compare categorical data. Associations between OH and mobility 
were analyzed using analysis of variance (ANOVA). Mean (log transformed) 
time to complete the TUG and FTSS were compared between fallers with 
and without OH. Model A was unadjusted; Model B was adjusted for age, 
sex and additionally identified covariates (p<0.01). Mean values were back 
transformed to original scale. Associations between OH and balance, 
functional dependency (ADL, iADL and use of walking aid) and fear of falling 
were analyzed using logistic regression analysis. Odds ratios (ORs) and 
corresponding 95% confidence intervals (95%CI) were computed using 
the same two models (A and B) as previously described. If any association 
was found between OH and physical performance, physical performance 
scores were compared across categories of blood pressure changes during 
orthostatic challenge using ANCOVA and/or multivariate logistic regression 
analyses with model A and B. A p-value <0.05 was considered statistically 
significant. 
Results
In total, 616 patients participated in the IMPROveFALL study. We excluded 
93 patients with no completed orthostatic challenge. Therefore, the study 
population consisted of 523 participants.
  Two hundred and sixty participants (49.7%) had OH. Characteristics 
of the study population are shown in table 1 stratified for the presence of 
OH. Participants with OH were older than participants without OH (p=0.006). 
Median age was 77.4 years [IQR 71.2–82.6] in those with OH and 75.4 years 
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[IQR 69.5–80.5] in those without OH. No differences were found in medical 
history, such as diabetes mellitus, cerebrovascular diseases and pulmonary 
diseases between participants with and without OH. Participants with 
OH tended to have cardiovascular disease more often (35.0% vs 27.8%, 
p=0.072). The MMSE score was higher in those with OH than those without 
OH. Median MMSE was 28 [IQR 26–29] in participants with OH and 27 [IQR 
25–29] in participants without OH (p=0.015). 
Table 1. Baseline characteristics (n=523)
Variable No OH (n=263) OH (n=260) p-value
Age, years 75.4 [69.5-80.5] 77.4 [71.2-82.6] p=0.006
Men, % 38.8 39.6 p=0.85
BMI*, kg/m2 27.1 [24.4-30.5] 27.0 [24.2-29.4] p=0.16
Smoking status 
  never, %  
  former, %  
  current, % 
 
54.0 
34.6 
11.4
 
52.7 
36.2 
11.2
 
p=0.93
Alcohol use 
  <1 unit/day, % 
  1-2 units/day, % 
  >2 units/day, %
 
62.7 
23.5 
14.1
 
63.5 
28.5 
8.1
 
p=0.06
Medical history
  Diabetes Mellitus, % 21.7 19.6 p=0.56
  Heart failure, % 3.0 4.2 p=0.47
  Cardiovascular disease, % 27.8 35.0 p=0.07
  TIA/CVA, % 18.6 14.6 p=0.22
  Pulmonary disease, % 13.3 13.1 p=0.94
MMSE, score 27 [25-29] 28 [26-29] p=0.015
Physical performance
TUG†, seconds 10.0 [8.0– 14.0] 10.0 [8.0– 13.0] p=0.55
FTSS‡, seconds 16.0 [12.0– 20.0] 15.0 [12.0– 20.0] p=0.70
Tandem test failed, % 35.1 37.7 p=0.54
ADL dependency§, % 24.3 31.1 p=0.08
iADL dependency§, % 41.2 44.0 p=0.50
Use of walking aid||, % 25.4 28.3 p=0.47
Fear of falling, % 30.4 38.8 p=0.043
Notes: Continuous variables are expressed as median and interquartile range. *BMI is available 
in 258 and 252 participants, respectively (n=510) † 239 and 234 participants were able to perform 
TUG, respectively (n=473) ‡ 226 and 212 participants were able to perform FTSS, respectively 
(n=438) § Information on (i)ADL dependency is available in 263 and 257 participants, respectively 
(n= 520) || Information on the use of a walking aid is available in 256 and 237 participants, 
respectively (n=493) Abbreviations: OH = orthostatic hypotension, BMI = Body mass index, 
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TIA = transient ischemic attack, CVA = cerebrovascular accident, MMSE = mini-mental-state-
examination, TUG = Timed-Up-and-Go, FTSS = Five-Times-Sit-to-Stand, ADL = activities of 
daily living, iADL = instrumental activities of daily living
Time needed to complete the TUG (n=473) did not differ between participants 
with and without OH (10.0 vs 10.0 seconds). Also, mean time to complete the 
FTSS (n=438) did not differ between participants with and without OH (15.0 
vs 16.0 seconds, respectively). In total, 37.7% of the participants with OH 
and 35.1% of the participants without OH failed to complete the tandem 
test (p=0.54). Participants with OH, were more often ADL-dependent with a 
borderline significance (31.1% vs 24.3%, p=0.08). No difference was found in 
iADL-dependency (44.0% vs 41.2%, respectively). Also the use of a walking 
aid did not differ between groups (28.3% vs 25.4%, respectively). Fear of 
falling was more frequent in participants with OH than participants without 
OH (38.8% vs 30.4%, p=0.043). 
  Vascular characteristics are presented in Table 2. Participants with 
OH had higher SBP and DBP at rest than participants without OH. Median SBP 
was 151 mmHg [IQR 140–170] and 145 mmHg [IQR 135–160], respectively 
(p<0.001). Median DBP was 80 mmHg [IQR 75–90] and 80 mmHg [IQR 74–
85], respectively (p=0.033).  
 
Table 2. Hemodynamic characteristics (n=523)
Variable No OH (n=263) OH (n=260) p-value
SBP at rest, mmHg 145 [135– 160] 151 [140– 170] p<0.001
DBP at rest, mmHg 80 [74– 85] 80 [75– 90] p=0.033
Heart rate at rest, bpm* 68 [60– 76] 70 [60– 76] p=0.23
Orthostatic test
  Delta SBP, mmHg -5.0 [-10.0– 0.0] -20.0 [-28.0– -15.0] p<0.001
  Delta DBP, mmHg 0.0 [-5.0– 5.0] -10.0 [-11.0– -5.0] p<0.001
Notes: Continuous variables are expressed as median and interquartile range *Heart rate is 
available in 262 and 251 participants, respectively (n=513) Abbreviations: OH = orthostatic 
hypotension, SBP = systolic blood pressure, DBP = diastolic blood pressure
Figure 1 shows mean time to complete the TUG and FTSS in participants 
with and without OH. In model A (figure 1A), mean time to complete the TUG 
did not differ between participants with and without OH with mean values of 
10.6 (95%CI 9.9–11.2) and 10.8 (95%CI 10.2–11.5) seconds, respectively. 
After adjustments for age, sex, use of alcohol, SBP in rest, MMSE score and 
history of cardiovascular disease in model B (figure 1B), estimates were only 
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slightly changed. Mean time to complete the FTSS did also not differ between 
participants with and without OH, using model A (figure 1C). In both groups, 
mean values were 16.2 (95%CI 15.4–17.1) seconds. In model B (figure 1D), 
also no differences were found between those with and without OH. 
Figure 1. Mean mobility scores in older fallers with and without orthostatic 
hypotension
Notes: Dots represent mean values, bars represent 95% confidence interval. Model A was 
unadjusted; Model B was adjusted for age, sex, alcohol use, systolic blood pressure in rest, 
Mini-Mental-State-Examination score and Cardiovascular disease. Abbreviations: OH = 
orthostatic hypotension, TUG = Timed-Up-and-Go, FTSS = Five-Times-Sit-to-Stand.
Table 3 presents ORs for low physical performance. In model A, the OR for 
failing the tandem test was 1.12 (95%CI 0.78–1.60) for participants with OH 
compared with participants without OH. For ADL- and iADL-dependence, 
ORs were 1.41 (95%CI 0.96–2.07) and 1.13 (95%CI 0.80–1.60), respectively. 
Also, the OR for the use of walking aid reached no statistical significance 
(OR 1.16, 95%CI 0.78–1.73). After adjustments using model B, estimates 
only slightly changed for these categories of physical performance. On 
the contrary, the OR for fear of falling was 1.45 (95%CI 1.01–2.09) for 
participants with OH compared with participants without OH using model 
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A (p-value=0.043). In model B, corresponding estimates were 1.48 (95%CI 
1.00–2.18) with a p-value of 0.049.
Table 3. Odds ratios for low physical performance in older fallers with 
orthostatic hypotension 
Failed  
tandem test
ADL  
dependency
iADL 
dependency
Use of  
walking aid
Fear  
of falling
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Model A
No OH 
(n=263) 1.00 1.00 1.00 1.00 1.00
OH 
(n=260)
1.12 
(0.78-1.60)
1.41  
(0.96-2.07)
1.13  
(0.80-1.60)
1.16  
(0.78-1.73)
1.45  
(1.01-2.09)
Model B
No OH 
(n=263) 1.00 1.00 1.00 1.00 1.00
OH 
(n=260)
0.99  
(0.67-1.50)
1.40  
(0.92-2.12)
1.09  
(0.73-1.61)
1.07  
(0.68-1.68)
1.48  
(1.00-2.18)
 
Notes: Model A was unadjusted; Model B was adjusted for age, sex, alcohol use, systolic 
blood pressure in rest, Mini-Mental-State-Examination score and Cardiovascular disease. 
Abbreviations: ADL= activities of daily living, iADL = instrumental activities of daily living, OH = 
orthostatic hypotension.
ORs for fear of falling were the highest in categories of a greater drop in DBP, 
whereas no association was found between drop in SBP and fear of falling 
(Table 4). There was no drop in DBP in 222 participants; in 141 participants, 
the drop was 1-9 mmHg; in 131 participants, the drop was 10-19 mmHg and 
in 29 participants, the drop was ≥20mmHg. In model A, corresponding ORs 
were 1.00, 1.13 (95%CI 0.71–1.80), 2.05 (95%CI 1.30–3.22) and 4.22 (95%CI 
1.89–9.45), respectively. In model B, estimates were only slightly changed. 
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Table 4. OR for fear of falling in older fallers within categories of postural 
changes of blood pressure
Fear of falling OR (95% CI)
Model A Model B*
Systolic blood pressure (SBP)
No drop SBP (n=113) 1.00 1.00
1-9 mmHg (n=71) 0.82 (0.44-1.54) 0.86 (0.45-1.66)
10-19 mmHg (n=151) 0.90 (0.54-1.51) 0.97 (0.57-1.65)
≥20 mmHg (n=188) 1.06 (0.65-1.72) 1.08 (0.64-1.82)
Diastolic blood pressure (DBP)
No drop DBP (n=222) 1.00 1.00
1-9 mmHg (n=141) 1.13 (0.71-1.80) 1.19 (0.74-1.92)
10-19 mmHg (n=131) 2.05 (1.30-3.22) 2.09 (1.29-3.38)
≥20 mmHg (n=29) 4.22 (1.89-9.45) 4.67 (1.93-11.33)
Notes: Model A was unadjusted; Model B was adjusted for age, sex, alcohol use, systolic or 
diastolic blood pressure in rest*, Mini-Mental-State-Examination score and Cardiovascular 
disease. *Model B investigating drop in SBP is adjusted for SBP in rest, whereas model B 
investigating drop in DBP is adjusted for DBP in rest.
 
Discussion
In the present study, we found that older fallers with OH are more likely 
to have fear of falling than older fallers without OH. The higher the drop in 
DBP, the higher the chances of having fear of falling up to circa 400%. No 
association was found between OH and physical performance evaluated as 
mobility, balance and functional (in)dependency.
  The prevalence of OH of 50% in these older fallers was comparable 
with previous literature. The prevalence of OH differs in different study 
populations of older persons and varies between 13 and 70% in geriatric 
outpatients.19 Previous studies have investigated the possible association 
between OH and physical performance in older persons. Those studies did 
not focus on older fallers specifically. However, results of our study are in line 
with these earlier findings. A recent systematic review and meta-analysis has 
made an overview of these studies.8 In the systematic review, less than half 
of the included studies showed an association between OH and physical 
functioning. In the meta-analysis, associations were found between OH and 
impaired balance and OH and ADL dependence, associations with other 
functional categories were less consistent. It needs to be pointed out that 
all included studies were conducted within community dwelling populations, 
nursing home residents or specific categories of patients such as geriatric 
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outpatients or inpatients and patients with parkinsonism. Older fallers 
might have been included in these studies, however, the results cannot be 
completely compared with our specific population of older fallers alone. 
Since it is expected that falls and related consequences are a growing health 
issue in the growing aging population,20-22 it might be relevant to focus on this 
specific population. 
  Only few studies have investigated the possible association between 
OH and the fear of falling in older adults. In a relatively small study including 91 
community dwelling adults, OH was present in 12% and fear of falling in 46% 
of the participants. No association was found between these variables.23 In 
another relatively small study of older patients with uncontrolled hypertension, 
21% of the patients were diagnosed with OH and circa 36% had fear of 
falling both in the OH group as in the non-OH group.24 In contrast to these 
two studies, the present study found an association between OH and fear 
of falling in older persons. This difference may be explained by the different 
study populations and also by the fact that the current sample size is circa 
three times larger. 
  A possible hypothesis regarding the association between the presence 
of OH and fear of falling may lie in the mechanisms of cerebral hypoperfusion. 
OH can cause symptoms of dizziness, postural lightheadedness and blurred 
vision as result of cerebral hypoperfusion.25 Also, chronic brain pathology, 
such as brain atrophy and white matter lesions, both more often present 
in those with OH,26 might influence the perception of verticality, resulting in 
subjective dizziness.27 In the present study, the drop of DBP seems to be 
the main factor driving this association. This association may be due to the 
role of DBP. During diastole, the coronary arteries are perfused.28 Low DBP 
may reflect poorer cardiac condition and also higher arterial stiffening.29,30 
Noteworthy, DBP is a steady component of blood pressure, determining 
strongly the mean arterial pressure (MAP), which maintain organs perfusion. 
When DBP is low, or drops during postural change, the lower MAP may result 
in comparable symptoms of hypoperfusion leading to fear of falling. It is not 
completely clear why we did not find an association between OH and other 
physical performances scores. It can be speculated that participants in the 
present study without OH, but with a serious fall, already have low physical 
performance scores, comparable with those with OH. It might be challenging 
to investigate the role of OH in physical performance in this selected group of 
(frail) older fallers. 
  This study has several limitations. First, the study design was cross-
sectional. Therefore, no conclusion can be drawn about causality. Second, 
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OH was measured with a calibrated sphygmomanometer and 1,2,3,4 and 
5 minute blood pressure values were documented. We did not include 
continuous blood pressure measurements, which are ideally recommended 
in guidelines.31 Therefore, this measurement may have underestimated 
the prevalence of OH. Third, differences in physical performances scores 
between the groups were small which might have limited the statistical 
power. The present study also has strengths. Different domains of physical 
performance were investigated giving an overview on different aspects of 
physical status. Both dynamic and static functionality tests were performed, 
functional dependency was scored and also a subjective measurement 
of physical performance, namely fear of falling, was investigated.18,32 No 
previous study has focused on the possible association between OH and 
physical performance test scores in older fallers. 
Conclusions and implications
Older fallers with OH are more likely to have fear of falling, especially those 
with a greater drop of DBP, whereas other measures of physical performance 
did not differ in older fallers with and without OH; Low DBP is associated with 
low coronary supply and possibly an impaired organ perfusion. Investigating 
this topic in this specific group of patients could help in understanding the 
mechanisms and consequences of such a multifactorial problem, namely 
falling, among older persons. Future studies including different categories 
of patients in larger study populations are needed to investigate these 
associations. 
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The kidneys and the arteries undergo age-related structural and functional 
changes which can be accelerated by traditional and non-traditional 
cardiovascular risk factors. 1,2 Therefore, aging is an extremely heterogeneous 
process involving various domains of physical and mental health. Traditional 
risk factors such as hypertension, hypercholesterolemia and diabetes 
mellitus are widely used by health care professionals to stratify the risk of 
cardiovascular diseases.3 Non-traditional risk factors on the other hand may 
be recognized as risk factors in the general population, such as inflammation 
and malnutrition, or be unique to patients with underlying diseases. As result, 
renal and vascular aging can have divergent impact in late life. 
  A decrease in kidney function and an increase of arterial stiffness 
are considered part of accelerated aging and are both associated with an 
increased risk of cardiovascular morbidity and mortality,4-6 but might also 
affect other highly relevant outcomes in older adults. The general aim of this 
thesis was to investigate consequences of renovascular changes in late life. 
The findings can contribute to a better estimation of kidney function in late 
life and to a better understanding of the possible impact of chronic kidney 
disease (CKD), arterial stiffness and blood pressure dysregulation on physical 
and mental health in older adults.
  The findings described in this thesis are based on three cohorts. The 
Improving Medication Prescribing to reduce Risk Of FALLs (IMPROveFALL) 
study is a randomized, multicenter trial conducted in The Netherlands between 
October 2008 and October 2011 assessing the effect of fall-risk-increasing-
drugs withdrawal versus ‘care as usual’ as a method for falls reduction. 
Participants were 65 years or older and visited the emergency department 
because of a fall. Baseline data of this study including 616 participants was 
used to investigate specific questions on renal and vascular aging in older 
adults who have fallen. The second study was conducted at the outpatient 
clinic of geriatric medicine of the Erasmus MC, University Medical Center 
in Rotterdam between April 2015 and June 2016 and included participants 
referring with functional and/or cognitive complaints. In this study, data on 
arterial stiffness and physical and cognitive functioning was collected in order 
to make a comprehensive overview on multiple health domains in late life. 
The Screening for CKD among Older People across Europe (SCOPE) study 
is a multicenter 2-year prospective cohort study involving 2461 community-
dwelling persons aged 75 years and over, visiting the outpatient clinics of 
participating institutions in 7 countries across Europe. Participants were 
included between August 2016 and February 2018 and underwent multiple 
clinical and laboratory evaluations. The design and rationale of this study 
is presented in this thesis. Findings presented in this thesis are based on 
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preliminary analyses of the baseline data of the European SCOPE database 
and of the baseline data of the Dutch subsample of the SCOPE study. 
 In this chapter, the main findings and clinical implications of these 
findings are discussed. Suggestions on directions for further research are 
also presented. Part one of this chapter will focus on renal aging and part two 
of this chapter will focus on vascular aging.
Part I Renal aging
With advancing age and as consequence of chronic diseases, the kidneys 
undergo structural and functional changes, such as sclerosis of the glomeruli 
and tubular atrophy.7 These changes affect the kidney function and result in 
a decline in glomerular filtration rate (GFR). The direct measurement of GFR 
(mGFR) involves infusion of ideal filtration markers such as inulin or iohexol.8 
Measuring the urinary or plasma clearance of these exogenous substances 
is complex, expensive and time-consuming. Therefore, equations have been 
developed to estimate GFR (eGFR) from endogenous blood serum markers 
that are filtered by the glomerulus;9 this method is easier, less expensive and 
quicker to execute in routine clinical practice. Most equations are based 
on serum creatinine as endogenous serum marker, a molecule that is freely 
filtered by the glomerulus. The production of creatinine depends on muscle 
mass and life style factors,8 which also results in variations in serum creatinine 
levels in different populations or even within persons over time (table 1). 
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Table 1. Variations in production of serum creatinine
Variable Serum creatinine levels
Aging Lowered
Sex 
    Men 
    Women
 
Reference 
Lowered
Race 
    Caucasian 
    African American
 
Reference 
Raised
Body composition 
    Normal 
    Muscular 
    Sarcopenic 
    Obese 
    Sarcopenic-obese
 
Reference 
Raised 
Lowered 
No effect 
Lowered
Chronic conditions 
   Malnutrition 
   Inflammation  
 
Lowered 
Lowered
Life style factors 
    Low physical exercise 
    Vegetarian diet
 
Lowered 
Lowered
To overcome some of these limitations that the use of serum creatinine 
entails, equations also include variables such as age, sex, race or body size 
as surrogates for muscle mass. Still, since aging is a very heterogeneous 
process, the currently used GFR equations are not completely generalizable 
and have to deal with inaccuracy especially in late life.
 The SCOPE study, presented in chapter 2.1, hopes to close essential 
gaps of knowledge on how to accurately assess kidney function in late life. 
Some evidence suggests that muscle mass independent markers, such as 
cystatin C, ß-trace protein and ß-2-microglobuline could better estimate 
GFR and predict negative outcomes.10 However, the usefulness and cost-
effectiveness of these filtration markers in screening older adults for CKD has 
not been investigated. Therefore, one of the specific objectives of the project 
is to assess these existing methodologies for CKD screening among older 
adults using real-life data from a European cohort of persons aged 75 years 
and over. Another specific objective of the SCOPE study is to investigate 
novel and potentially useful application of existing and innovative biomarkers 
of CKD in late life. This study focusses on untargeted metabolomics and 
proteomics analyses in serum and urine. Longitudinal analyses, not yet 
presented in this thesis, will likely provide a panel of completely novel 
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and strong kidney damage biomarkers that may substantially improve 
the identification of older adults at particular risk of CKD progression and 
cardiovascular events. Eventually, the systematic use of a comprehensive 
geriatric assessment (CGA) makes it possible to investigate consequences 
of CKD on multiple domains of health status.
 
Main findings and clinical implications 
In chapter 3.1 preliminary results of the SCOPE study are presented, which 
focused on to what extent CKD may be staged interchangeably by different 
currently used eGFR equations. Creatinine-based eGFR was calculated 
with three equations that are also used in daily practice: the CKD-EPI-, the 
BIS1- and the FAS-equation. The Bland-Altman analysis showed a small 
bias between the BIS1- and the FAS-equation, however, the bias between 
the CKD-EPI and the other two equations was very significant and peaking 
around 60mL/min. Since this is also the threshold for diagnosing CKD, 
these findings have highly interesting implications in daily clinical practice. 
Most interestingly, the difference between the CKD-EPI and the other two 
equations increased with decreasing levels of muscle mass. 
  In daily practice, clinical laboratories all over the world use the 
CKD-EPI-equation as recommended by the 2012 KDIGO Guidelines for the 
Evaluation and Management of CKD.9 This recommendation is based on a 
systematic review that was published in 2012 that concluded that the use of 
the CKD-EPI equation was favored above the Modification of Diet in Renal 
Disease (MDRD) study-equation, despite the fact that neither the CKD-EPI- 
nor the MDRD-equation is optimal for all populations and GFR ranges.11 A 
meta-analyses of data from 1.1 million adults endorses this recommendation.12 
The study of Matsushita et al found that the CKD-EPI-equation gave a more 
accurate GFR estimation then the, up till then, world-wide most commonly 
used MDRD-equation. A mildly reduced kidney function decline was more 
accurately categorized and in contrast to the MDRD-equation, the CKD-
EPI-equation was also validated for persons above 70 years. However, one 
aspect of the validation of the CKD-EPI might not have received sufficient 
attention when it comes to the use of this equation in older adults: during 
the development of the CKD-EPI, only 4% of the study population was 
aged above 70 years and information on comorbidities (except for diabetes 
mellitus) was not known.13 Therefore, the question raises: are we currently 
ready to estimate kidney function in late life?
  Factors like age, sex and body mass index are already implemented 
in existing equations, but there still seems to be a large variation between 
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equations and subsequent eGFR values in older adults. Loss of muscle mass, 
which is common in frail older adults, results in low levels of serum creatinine 
even despite a depressed GFR. Current equations do not seem capable to 
account for this. eGFR equations are working well in the populations in which 
they have been developed; the BIS1-equation was specifically developed in 
a population of people aged 70 year and older,14,15 whereas the FAS-equation 
was developed in a Full Age Spectrum (FAS).16 Still, our findings suggest to 
be careful with interpretation of creatinine based eGFR values in late life. 
Most of the time, only data for creatinine-based eGFR equations is provided 
and in that case health care professionals treating older adults should be 
encouraged to use the BIS1- or FAS-equation to assess the kidney function. 
 In chapter 3.2 multiple elements of physical performance were 
compared across different stages of CKD in older persons. It was investigated 
whether creatinine-based eGFR values were associated with handgrip 
strength, mobility scores and calf circumference, as markers of muscle 
strength and muscle mass. A smaller calf circumference and up to 10% lower 
grip strength was found in older adults with an eGFR value ≥90 mL/min when 
compared to older adults with an eGFR value of 60-90 mL/min and <60mL/
min. Findings were the most striking while using the MDRD-equation to 
estimate GFR, but similar results were also found with the CKD-EPI-equation.
It is widely known that decreased kidney function is associated with negative 
outcomes such as an increased risk of morbidity and mortality,4 but also 
with chronic inflammation, malnutrition and progressive loss of muscle mass 
and strength,17,18 whereas higher GFR values are less associated with these 
negative outcomes. However, in the study in chapter 3.2, older persons with 
the best estimated kidney function, had the worst physical performances 
scores. These findings suggest that low serum creatinine and high eGFR 
values might represent older persons with less lean muscle mass and not 
necessarily older persons with good filtration rates. 
  In this study, persons aged 65 years and over were included and 
the mean age was 76 years; it is expected that in higher age ranges, results 
might be amplified. Previous literature supports this hypothesis. A large 
study population of community-dwelling persons in Italy investigated the 
relationship between eGFR, using the BIS1-equation, physical performance 
and mortality in the very oldest old of 90 years and over.19  Still, even when 
using the BIS1-eGFR, a more reliable eGFR-equation in older adults, an 
U-shaped relationship was found between eGFR and mortality, suggesting 
that sarcopenic persons might cluster in the group with higher eGFR values. 
Mortality in this group was mainly a result of respiratory and neoplastic 
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diseases, which are both associated with cachexia and sarcopenia. Indeed, 
they also demonstrated that the oldest old adults with an eGFR >60 mL/min 
and <30 mL/min had the lowest muscle strength. 
   It once more suggests that lower muscle mass is likely to overestimate 
kidney function using eGFR-equations in (frail) older adults and the use of any 
creatinine-based eGFR equation at older age should be seriously questioned.
 With the start of chapter 4.1, the focus was shifted from kidney 
function and physical health to kidney function and mental health, another 
important outcome related to late life well-being. There is increasing evidence 
linking CKD, cognitive impairment and mood disorders in older adults;20,21 
the kidneys and the brain can be affected by shared risk factors, such as 
hypertension and diabetes mellitus, and the aging process also profoundly 
affects both.22 Early identification of modifiable risk factors of cognitive and 
functional decline such as CKD is of interest in order to be able to screen 
for mediators in this association. As follows, therapeutic strategies in 
patients with CKD but also in patients with (an increased risk of) dementia or 
depression can be optimized.
  The link between kidney function decline, cognitive impairment and 
depressive symptoms seems to be mediated through vascular mechanisms 
including small vessel disease.22 Consequences of CKD such as metabolic 
dysregulation, anemia and inflammation might also affect the brain.23 The 
hypothesis in this European study in outpatients aged 75 years and over was 
that cognitive impairment and depressive symptoms would be more prevalent 
in those in advanced stages of CKD than in those in earlier stages. It was 
also hypothesized that older adults with cognitive impairment and depressive 
symptoms would have lower levels of eGFR than those without. Surprisingly, 
within the framework of the SCOPE study, these hypotheses could not be 
confirmed. As one would expect, the prevalence of conditions closely linked 
to (cerebral) small vessel disease such as atrial fibrillation, congestive heart 
failure and history of stroke, increased with the severity of CKD. Despite 
this fact, these conditions did not mediate an association between kidney 
function, cognitive impairment and depressive symptoms.
  Most previous cross-sectional studies that found associations 
between kidney function and mental health did not focus on older persons 
specifically and this might explain the differences in results; when focusing 
on persons in late life only, a bias might be introduced in which individuals 
with CKD in more advanced stages and possibly cognitive impairment 
and/or depressive symptoms already died or were more likely to decline 
participation. Subsequently, those adults were not included in the SCOPE 
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study, a study with an extensive study protocol, which made it more difficult 
to find significant associations.
  It must be emphasized that there are numerous challenges when 
investigating the possible impact of kidney function in late life. The optimal 
method for estimating GFR is not yet present and therefore it is important 
to interpret results with caution. In addition, there is a large selection of 
methods that can be used for assessing cognitive function or depressive 
symptoms, which might also explain divergent results in previous studies. 
In this study, the Mini-Mental-State-Examination (MMSE) and the Geriatric 
Depression Scale (GDS) were used to assess cognition and the presence 
of depressive symptoms, respectively. It cannot be excluded that the 
use of other tools to evaluate cognition and mood might also have given 
different results. Ideally, a complete neuropsychological evaluation should be 
used to assess all cognitive domains. With such complete data we might 
be able to confirm the link between the kidney and the brain at older age. 
 
Future directions
The studies in this thesis demonstrated that creatinine-based eGFR 
equations have to deal with inaccuracy when used in older adults, mainly 
as consequence of progressive loss of muscle mass in older adults and the 
heterogeneity of the aging process. A given patient needs to be classified into 
the true stage of CKD to provide the best therapeutic strategies, considering 
that misclassification has highly relevant clinical implications. Therefore, it is 
of paramount importance to find new muscle mass independent markers to 
accurately assess kidney function in late life.
 The last two decades the interest and research in other biomarkers 
of kidney function is growing, especially cystatin C has been investigated,24,25 
in an attempt to improve the accuracy of equations. Equations with both 
creatinine and cystatin C improved the prediction of mGFR when compared 
to equations that were only creatinine-based, also among older adults.26 
However, when adding cystatin C to the equation, the concordance between 
equations only marginally improves and the prognostic accuracy remained 
unchanged.27,28 There is still a gap of knowledge on how to estimate kidney 
function accurately in older adults; a gap that the SCOPE study is aiming 
to fill. This study is likely to provide novel and strong kidney damage 
biomarkers to substantially improve the equations for older adults. Existing 
biomarkers of CKD will be explored like cystatin C, ß-trace protein and ß2-
microglobuline.24,29 Potential new biomarkers in serum and urine based on 
metabolomic and proteomic determinations or other techniques will also be 
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evaluated following the indications arising from two major studies that are 
currently performed: PIVUS and ULSAM.30,31 Investigation of new biomarkers 
in various populations in both the community and hospital setting would be 
interesting in order to be able to make an ideal equation to estimate GFR. 
The ideal equation should be accurate, easy to use, low-cost and preferably 
generalizable.
  Studies in this thesis also focused on associations between kidney 
function, functional and cognitive decline. We were not able to confirm our 
hypothesis that persons in advanced stages with CKD were more likely 
to have cognitive impairment and/or depressive symptoms. However, it is 
still likely that these conditions share common mechanisms, also in late 
life. Longitudinal studies are needed to establish causal inference, in which 
kidney function should be measured or accurately estimated. In order to 
do so, longitudinal analysis with data of the SCOPE study will hopefully 
contribute; within the data of the SCOPE study it is possible to investigate 
the effect of kidney function, assessed with mGFR or newly developed eGFR 
equations, on mental health. It might be of interest to investigate effects of 
CKD progression on cognitive impairment and depressive symptoms. Ideally, 
studies with a long follow-up might help to gain additional knowledge on 
these links in late life. 
Part II Vascular aging
The aging process induces multiple physiological changes in the arterial wall, 
which is most evident in the large central arteries: a decreased distensibility 
(by breaks in elastin) and an increased wall thickness (by accumulation 
of collagen) result in an increase of arterial stiffness.32 Cardiovascular risk 
factors such as hypertension and diabetes mellitus have additional impact on 
the arterial wall structure and act as an age-accelerator on the progression of 
arterial stiffness.33,34
  The effect of arterial stiffness has been widely studied, demonstrating 
that hemodynamic changes as consequence of elevated arterial stiffness 
increases the risk of clinical and subclinical cardiovascular morbidity and 
mortality. 6,35-37 An overview on determinants of arterial stiffness, characteristics 
of the arterial wall and related consequences of these changes are presented 
in table 2. However, the potential impact of arterial stiffness and blood 
pressure dysregulation on physical and mental health in late life deserves 
additional attention and needs to be elucidated.
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Table 2. Determinants, characteristics and consequences of aging of the 
arteries
Determinants Characteristics Consequences
Age38
Genetic background39
Life style factors
  Low physical exercise40
  Smoking41 
Hypertension42
Diabetes Mellitus43
Hypercholesterolemia44
Metabolic syndrome45
Chronic kidney disease46
Inflammation47
Arterial wall33
  Endothelial dysfunction
  Elastin breakdown
  Collagen accumulation
  Smooth muscle cell   
  dysfunction
  Calcification
  Fibrosis
Arterial lumen33
  Increase diameter
Orthostatic hypotension48  
Change of BP profile49 
  Increase SBP 
  Decrease DBP
  Increase PP
Long-term effect on target organs  
  Myocardial infarction50
  Heart failure51
  Stroke50
  Dementia52
  Chronic kidney disease53
  Mortality6
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; SBP, 
systolic blood pressure
 
Main findings and clinical implications 
Whereas the effects of elevated arterial stiffness on cardiovascular outcomes 
are extensively studied, less is known about the effect of arterial stiffness 
on other organs. In chapter 5.1 an in-depth review provided an overview 
on possible shared mechanism underlying the association between arterial 
stiffness, bone demineralization and muscle loss. This narritive review showed 
that there is no clear consensus on how these processes interact, but several 
hypotheses are described, such as the impact of immunosenescence, 
hormonal dysregulation and impaired glucose metabolism on all three 
processes. 
  So far, mainly cross-sectional studies have investigated these 
associations, which makes it not clear whether bone and muscle loss are just 
age-related processes parallel to vascular aging or whether these processes 
share common pathways or even directly influence one another. 
  Our review demonstrated that most cross-sectional studies have 
adjusted for multiple potential confounders, including age, in which an 
independent association remained. This suggests that there might be a 
link between arterial stiffness, bone demineralization and muscle loss aside 
from aging. Information from longitudinal studies is scarce, which it makes it 
difficult to draw conclusions about causality. 
  One longitudinal study was conducted in The Netherlands and 
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investigated the impact of aortic stiffness on change in bone mineral density 
(BMD) within 2 years.54 In this study no associations were found, whereas in 
Japan, women with increased arterial stiffness after 10 years of follow-up 
had lower BMD levels at baseline in multivariate analysis.55 These findings 
suggest an independent role of bone demineralization in determining arterial 
stiffness. Hypotheses on how bones would affect the vessels is, unfortunately, 
not presented, but the findings still have relevant implications; women with 
low bone mineral density should be examined for cardiovascular disease, 
since they seem to have a higher risk of development of arterial stiffness and 
(secondary) cardiovascular diseases. 
  To the best of our knowledge, only one study investigated the role 
of arterial stiffening on muscle loss.56 This study demonstrated that arterial 
stiffness is associated with a higher risk of sarcopenia within 6 years of follow-
up, independently of age and cardiovascular risk factors, but a significant 
role was played by chronic inflammation, as seen by high levels of pro-
inflammatory cytokines on muscle mass decline over time. 
  All in all, common pathways are probable and considerable 
research is needed to further investigate this topic. Interventions acting on 
common pathways can be helpful to prevent further decline of arterial elastic 
properties, bone density and muscle mass and related frailty. It is possible 
that interventions such as physical exercise and optimizing nutritional status 
could have a positive direct mechanical effect on muscles and bones but 
also through an effect on common pathways as inflammation and insulin 
resistance.
 In chapter 5.2, health-related quality of life was investigated in the 
Dutch subsample of the SCOPE study. Indicators of aortic stiffness, aortic 
pulse wave velocity and central pulse pressure were compared between 
adults who did not report any problems in quality of life and adults with an 
impaired quality of life. Both indicators of aortic stiffness were associated with 
an impaired quality of late life, independent of age, blood pressure levels and 
comorbidities. Quality of life is often used as an overarching term to qualify 
diverse domains in life such as physical, emotional, mental and functional 
well-being and an important endpoint in medical care.57 It is likely that aortic 
stiffness plays a role in multiple domains and could therefore be seen as an 
independent tissue biomarker of vitality status in late life.
  It can be hypothesized that subclinical vascular changes could be 
revealed in measures of quality of life before resulting in clinical cardiovascular 
comorbidities. Aortic stiffness can negatively impact physical health; 
aortic stiffness and consequent hemodynamic changes play a role in the 
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development and progression of end-organ diseases and have an impact on 
the heart, the kidneys and the brain.49,58 A relatively small increase in aortic 
stiffness and consequent hemodynamic changes could result in a subclinical 
stage of cardiovascular morbidity affecting the physical part of quality of life. 
These same changes can also lead to cerebral small vessel disease which is 
associated with depressive symptoms and cognitive impairment;52,59 if this is 
the case, clinical or subclinical, aortic stiffness might have a negative impact 
on mental health and consequent quality of life. 
  It cannot be excluded that impaired quality of life could also affect 
vascular properties and increase arterial stiffness. Lower quality of life might 
result in a lower treatment compliance due to lower social support of more 
depressive symptoms,60,61 which could deteriorate (vascular) health. In 
addition, a physically inactive lifestyle,62 often seen in persons with a lower 
quality of life, also has a negative impact on the arteries. 
  The findings presented in this chapter suggest that aortic stiffness 
measurements could be added as a routine non-invasive tool for clinical 
assessment of older adults to identify those in a subclinical stage of 
cardiovascular diseases. Then, targeted therapeutic strategies might avert 
further deterioration in late life.
 In chapter 5.3, a study in older adults with cognitive and functional 
complaints is presented in which associations between indicators of aortic 
stiffness and brain integrity was investigated. Both gray matter volume 
(GM) and the severity of cerebral white matter lesions (WML) were areas of 
interest; no previous studies investigated these outcomes in older adults 
simultaneously with advanced techniques computing GM and WML volumes. 
Higher aortic stiffness, assessed as aortic pulse wave velocity and central 
pulse pressure, was partly associated with a higher load of cerebral WML and 
lower GM volumes independent of blood pressure levels. The association 
was strongly mediated by age. 
  Age plays an important role in functional and structural changes of 
the brain throughout life. Loss of gray matter appears to be constant in adult 
life, whereas white matter increases in the first four decades of life, but then 
rapidly decreases after the age of 60 years.63,64 Lesions in the white matter 
can be seen on magnetic resonance imaging (MRI) even in the healthy aging 
brain, but it is likely that aged gray and white matter are more susceptible 
to age-related vascular changes such as aortic stiffness. Elevated aortic 
stiffness increases the pulsatile pressure and flow load leading to cerebral 
microvascular damage which contributes to the pathogenesis of cerebral 
small vessel disease.37,65 More indirectly, high pressure induces an increase in 
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vascular resistance which might lead to ischemia in the long term.66 Atrophy of 
gray matter might be the result of damage to small arteries in the brain caused 
by advanced vascular disease.67 Age is an important factor as result of a 
cumulative exposure to risk factors and probably acts in a common pathway 
leading to a deterioration of vascular properties and brain integrity. A better 
understanding of risk factors contributing to gray matter and white matter 
changes during the aging process could help to focus on specific pathways 
and to inhibit the progression of various neurodegenerative or behavioral 
disorders. With this knowledge, targeted strategies, which for example focus 
on decreasing aortic stiffness, could be deployed to prevent an accelerated 
functional decline or to even preserve functional independence in late life. 
This in turn can be closely linked to a satisfying quality of life and a reduced 
risk of adverse events. 
 In the study presented in chapter 6.1, the role of orthostatic 
hypotension was investigated in older adults who were referred to the 
emergency department as a consequence of an accidental fall. The hypothesis 
in this study was that the age-related blood pressure postural dysregulation 
might influence physical performance and fear of falling in older persons who 
have fallen. Older adults with orthostatic hypotension were more likely to have 
fear of falling than adults without orthostatic hypotension. During postural 
changes, the magnitude of the drop in diastolic blood pressure increased 
the risk of having fear of falling up to 400%, whereas the role of the drop in 
systolic blood pressure seemed to be less relevant. These findings suggest 
that vascular aging leading to diastolic blood pressure dysregulation during 
postural changes has relevant implications in late life. 
 Low diastolic blood pressure is more often found in late life and 
associated with a poorer cardiac condition and higher arterial stiffening.68-70 
Diastolic blood pressure also strongly determines mean arterial pressure, 
which function is to maintain organs perfusion and function.71 A low diastolic 
blood pressure or a greater drop in diastolic blood pressure during postural 
changes negatively influences organs perfusion which might result in 
cerebral hypoperfusion or related symptoms of orthostatic intolerance, such 
as lightheadedness, blurred vision and vertigo.72,73 Cerebral hypoperfusion 
and/or orthostatic intolerance might be the underlying mechanism in the 
association between the diastolic blood pressure dysregulation during 
postural changes and fear of falling as these symptoms  might trigger the 
sensation of fear of falling. 
  A recent review showed that fear of falling should not only be 
considered as a by-product of falls.74 Fear of falling has an independent 
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effect on quality of life and thus on perceived well-being of older adults. Our 
findings contribute to a better understanding of mechanisms underlying fear 
of falling and thus suggest that the measurement of blood pressure profiles 
during postural change could have an important place in comprehensive 
assessments of the vitality status of older adults. Fear of falling and underlying 
factors are likely modifiable risk factors of an impaired quality of life and could 
therefore be targeted in interventions to improve or maintain quality of life.
 
Future directions
The studies in this thesis demonstrated that vascular aging plays a role in 
multiple health domains of physical and mental health in late life. Arterial 
stiffness modifies blood pressure profiles and can be accompanied by diastolic 
blood pressure dysregulation during postural changes which may result in 
an impaired quality of late life. Immunosenescence, hormonal dysregulation 
and impaired glucose metabolism are underlying shared mechanisms linking 
vascular aging and deterioration of physical and mental health and could be 
of interest in new preventive and therapeutic targets in order to slow down 
these processes and prevent frailty.  
   Future studies are needed in diverse study populations of older 
adults in clinical setting and in the general older population to confirm and 
further explore our cross-sectional results. Experimental studies and long-
term longitudinal studies are needed to clarify causal inference and underlying 
shared pathways with aging. Studies should focus on the reduction of 
arterial stiffness and the effect on mental and physical health. It is possible 
that associations are mediated through direct mechanical effects of arterial 
stiffness on the bones, muscles and other organs, however experimental 
studies should also focus on targeting underlying pathways such as of 
chronic inflammation and insulin resistance; the effect of medication targeting 
signaling pathways could be evaluated, but it is also necessary to involve 
life style improvement such as promoting physical exercise and a good 
nutritional status in future studies on consequences of vascular aging in late 
life. Aging itself is a process with cumulative exposure to risk factors in which 
age cannot be targeted to improve outcomes. However, by identifying which 
underlying pathways are involved in accelerated aging, we might be able to 
maintain a good physical and mental health in late life. 
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Both the kidneys and the arteries undergo age-related alterations. 
  The deterioration of kidney function, determined as the glomerular 
filtration rate (GFR), can be accelerated by risk factors such as diabetes and 
hypertension, which can lead to chronic kidney disease (CKD). Measuring 
GFR is complex, therefore various equations based on serum creatinine are 
used in clinical practice to estimate kidney function. Creatinine is produced 
at a constant rate and continuously filtered by the kidneys and is therefore 
considered the most important surrogate marker for kidney function. 
However, the production of serum creatinine depends on sex, age and body 
composition and most equations have not been validated above the age of 
70 years. The use of creatinine-based equations to estimate kidney function 
at older age should be seriously questioned since body composition changes 
significantly with age. Part of this thesis aims to investigate the implications 
of the use of these equations in late life. 
  Stiffening of the arteries is also an age-related process, in which 
the same risk factors as in kidney function decline are involved. As result, 
structural and functional vascular changes can occur at an accelerated 
rate, causing arterial stiffness to increase even further. Increased arterial 
stiffness modifies blood pressure profiles with an increase in systolic blood 
pressure and a decrease in diastolic blood pressure as result. Many studies 
have been conducted showing that these hemodynamic changes can lead 
to cardiovascular morbidity and mortality. However, less is known about 
consequences of arterial stiffness and hemodynamic alterations in late life, 
especially on non-cardiovascular outcome measures. Part of this thesis 
therefore focuses specifically on the consequences for physical and mental 
health at older age, outcome measures that are important for older adults.
 After a general introduction on both renal and vascular aging in 
chapter 1, part I of this thesis, consisting of chapters 2, 3 and 4, starts with 
the focus on renal aging. 
  In chapter 2.1 the protocol of the SCOPE study is described, a 
multicenter observational study in seven countries across Europe focusing 
on screening for CKD in adults over 75 years of age. The aim of this study 
is to investigate both existing methods and new biomarkers to screen for 
CKD. In addition, the laboratory and biomarker results will be compared 
with medical and functional data collected during a comprehensive 
geriatric assessment. This study, in which 2461 older adults were included 
and followed-up for two years, hopes to provide evidence for a better 
European guideline with recommendations on how to screen for CKD 
in late life and how to deal with CKD and its consequences at older age. 
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Chapter 3 describes two studies that both address the clinical implications 
of estimating GFR based on creatinine in older adults. In chapter 3.1 the 
first and preliminary results of the SCOPE study are presented. In this study 
it was investigated to what extent CKD may be staged interchangeably by 
three different equations. Our results showed that the CKD-EPI equation was 
significantly different from the BIS1 and FAS equation. The biggest difference 
was found around the estimated GFR value of 60 mL/min, the threshold 
used to diagnose CKD. About 40% of the participants above this threshold 
with the CKD-EPI equation were below this threshold with the BIS1 and 
FAS equation. Furthermore, this study showed that the differences between 
equations increased even further in older adults with low muscle mass. These 
results demonstrate that creatinine-based equations to estimate kidney 
function at older age are not easily interchangeable and the main source 
of discrepancy between equations is muscle mass. In chapter 3.2, muscle 
strength and muscle mass were compared in older adults who had fallen. In 
this study, it was investigated whether hand grip strength, mobility scores 
and calf circumference differed across older adults in different categories 
of estimated GFR. Our results showed that older adults with the highest 
kidney function had up to 10% less strength and one centimeter smaller 
calf circumference than the older adults in lower categories. These findings 
were the most striking while using the MDRD-equation, but similar results 
were also found with the use of the CKD-EPI equation. These results suggest 
that lower muscle strength and mass in older patients is likely to lead to 
an overestimation of kidney function. This study once again underlines the 
need to search for muscle mass independent biomarkers to accurately reflect 
kidney function in the older population. 
 In chapter 4.1, the focus was shifted from kidney function and 
physical health to kidney function and mental health, another relevant outcome 
at older age. Baseline data of the SCOPE study was used to investigate 
associations between kidney function, cognition and mood. Deterioration of 
all these functions may be mediated through vascular mechanisms affecting 
the microcirculation of high-flow organs such as the kidneys and the brain. 
Surprisingly, our results do not confirm this hypothesis; cognitive impairment 
and depressive symptoms were not more prevalent in older adults in advanced 
stages of CKD and, vice versa, older adults with cognitive impairment and 
depressive symptoms had the same values of estimated GFR as older adults 
without problems with cognition and mood. However, since this study also 
used creatinine-based equations to estimate GFR, the hypothesis should 
ideally be retested with another method that more accurately reflects kidney 
function.
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Part II of this thesis, covering chapters 5 and 6, focuses on vascular aging. 
 Chapter 5 consists of three parts in which the possible impact of 
arterial stiffness is described with particular regard to various (organ)systems 
and overall quality of late life.  
 Chapter 5.1 describes possible links between arterial stiffness on 
the one hand and bone demineralization and muscle loss on the other hand 
in a narrative review. A large number of clinical studies reported associations 
and these found associations were mostly independent of age and other 
(potential) risk factors. However, based on previous literature, it emerged 
that it is not completely understood how these processes, all age-related, 
interact. Possible hypotheses we describe include the role of the immune 
system, hormonal changes and impaired glucose metabolism. These factors 
may accelerate the processes of vascular aging and bone- and muscle 
loss. Only limited longitudinal studies have been performed which makes 
it hardly possible to investigate causal relationships. However, the in-depth 
overview of possible hypotheses underlying these associations, suggests 
that interventions targeting the underlying factors could help to slow down 
these processes and thereby prevent consequent complications. 
 In the study in chapter 5.2 we investigated the association between 
indicators of aortic stiffness and quality of life. We found that older adults 
with an impaired quality of life had higher values of aortic stiffness than older 
adults with an optimal quality of life independent of age and comorbidity. 
These results suggest that aortic stiffness can be seen as a subclinical 
biomarker of late life vitality probably due to its negative impact on physical 
and mental health. 
 The study in chapter 5.3 describes possible associations between 
aortic stiffness, cerebral gray matter volume and white matter lesions. Higher 
aortic stiffness was associated with lower gray matter volumes and a higher 
load of white matter lesions. This association was independent of blood 
pressure, but strongly mediated by age. Age can probably be seen as the 
key player in stiffening of the arteries which also negatively influences brain 
integrity.  
  Whether altered blood pressure profiles also (negatively) impact 
late life is described in chapter 6.1. We found that a drop in diastolic blood 
pressure during postural changes was associated with an increased risk of 
have fear of falling: the higher the drop of diastolic blood pressure, the greater 
the risk of having fear of falling. This association was not found between 
systolic blood pressure changes and fear of falling. These results suggest that 
diastolic blood pressure dysregulation most likely has relevant implications 
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in late life and thus a better regulation of diastolic blood pressure could be a 
relevant target in trying to maintain quality of life at older age. 
  To conclude, chapter 7 contains a general discussion of the studies 
described in this thesis. This thesis provides new insights in underlying 
patterns that may be involved in the (accelerated) aging process in an attempt 
to unravel new targets for better diagnostic and therapeutic strategies to 
maintain or even improve quality of late life. 
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Zowel de nieren als de bloedvaten ondergaan veranderingen gedurende het 
verouderingsproces. 
  De verslechtering van de nierfunctie, uitgedrukt als de glomerulaire 
filtratie snelheid (GFR), kan versneld worden door risicofactoren als diabetes 
en hypertensie wat kan leiden tot chronische nierziekte met alle mogelijke 
gevolgen van dien. Het meten van de GFR is complex, daarom wordt er in 
de klinische praktijk gebruik gemaakt van diverse formules gebaseerd op 
serum kreatinine om de nierfunctie te schatten. Kreatinine wordt met een 
vrij constante snelheid geproduceerd en continue door de nieren uit het 
bloed gefilterd en wordt om die reden gezien als de belangrijkste surrogaat 
marker voor de nierfunctie. Echter, de productie van kreatinine is afhankelijk 
van geslacht, leeftijd en lichaamssamenstelling en de meeste formules zijn 
niet gevalideerd boven de 70 jaar. Het gebruik van formules gebaseerd op 
kreatinine om de nierfunctie te schatten op oudere leeftijd dient in twijfel te 
worden getrokken omdat het lichaam sterk veranderd met het ouder worden. 
Een deel van dit proefschrift richt zich dan ook op het onderzoeken van de 
gevolgen van het gebruik van deze formules in het late leven. 
  Verstijving van de slagaders is een ander aan de veroudering 
gerelateerd proces, waarbij dezelfde risicofactoren als bij 
nierfunctieverslechtering een rol spelen. Hierdoor kunnen structurele en 
functionele vasculaire veranderingen versneld optreden waardoor de 
verstijving van de vaten (nog) verder toeneemt. Als gevolg van verstijving 
van de slagaders veranderen ook de bloeddruk profielen met een verhoging 
van de systolische bloeddruk en verlaging van de diastolische bloeddruk 
als resultaat. Er zijn veel onderzoeken verricht die aantonen dat deze 
hemodynamische veranderingen kunnen leiden tot cardiovasculaire 
aandoeningen en mortaliteit. Echter, er is minder bekend over gevolgen van 
verstijving van de slagaders en hemodynamische veranderingen in het laten 
leven, met name op het gebied van niet-cardiovasculaire uitkomstmaten. 
Een deel van dit proefschrift richt zich dan ook specifiek op de gevolgen 
voor fysieke en mentale gezondheid op oudere leeftijd, uitkomstmaten die 
belangrijk zijn voor de oudere mens. 
 Na een algemene inleiding over zowel renale als vasculaire 
veroudering in hoofdstuk 1, start deel I van het proefschrift bestaande uit de 
hoofdstukken 2, 3 en 4 dat zich focust op renale veroudering.
  In hoofdstuk 2.1 wordt het protocol van de SCOPE studie beschreven, 
een multicenter observationeel onderzoek in zeven landen in Europa dat 
zich richt op het screenen op chronische nierziekte bij 75-plussers. Deze 
studie heeft als doel om zowel bestaande methoden als nieuwe biomarkers 
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te onderzoeken voor het screenen op chronische nierziekte. Daarbij wordt 
het laboratorium- en biomarker onderzoek vergeleken met medische en 
functionele data die middels een structureel geriatrisch onderzoek worden 
verzameld. Deze studie, waarin 2461 ouderen werden geïncludeerd en 
gedurende 2 jaar opgevolgd werden, hoopt bewijs te kunnen leveren voor 
een betere Europese handleiding met aanbevelingen over hoe het beste te 
screenen op chronische nierziekte in het latere leven en hoe het beste om te 
gaan met chronische nierziekte en de gevolgen voor de oudere mens. 
  Hoofdstuk 3 beschrijft twee studies die ingaan op de klinische 
implicaties van het schatten van de GFR op basis van kreatinine op 
oudere leeftijd. In hoofdstuk 3.1 werden de eerste voorlopige resultaten 
van de SCOPE studie gepresenteerd. Hier werd onderzocht in welke mate 
drie verschillende formules uitwisselbaar zijn om chronische nierziekte te 
categoriseren. Onze resultaten lieten zien dat de CKD-EPI formule significant 
verschilde van de BIS1 en de FAS formule. Het grootste verschil werd 
gevonden rondom de geschatte GFR waarde van 60 mL/min, de grens die 
gebruikt wordt voor het vaststellen van chronische nierziekte. Circa 40% van 
de deelnemers die boven deze grens zaten met de CKD-EPI formule werden 
wel onder de grens bevonden met de BIS1 en de FAS formule. Bovendien liet 
dit onderzoek zien dat de verschillen tussen formules nog verder toenamen 
bij hen met lage spiermassa. Deze resultaten tonen aan dat op kreatinine-
gebaseerde formules om de nierfunctie te schatten op oudere leeftijd niet 
goed uitwisselbaar zijn en de grootste bron van discrepantie tussen formules 
door spiermassa komt. In hoofdstuk 3.2 werden spierkracht en spiermassa 
vergeleken in ouderen die waren gevallen. In dit onderzoek werd gekeken 
of handknijpkracht, mobiliteit en kuitomvang verschilden tussen ouderen 
in verschillende categorieën van geschatte GFR. Onze resultaten lieten 
zien dat ouderen met de allerbeste nierfunctie wel tot 10% minder kracht 
hadden en één centimeter smallere kuitomvang dan de ouderen in een lagere 
categorie. Deze bevindingen waren het meest uitgesproken met de MDRD-
formule, vergelijkbare resultaten werden ook gevonden met de CKD-EPI 
formule. Deze resultaten suggereren dat lagere spierkracht- en massa bij 
oudere patiënten waarschijnlijk leidt tot een overschatting van de nierfunctie. 
Dit onderzoek onderstreept nogmaals de noodzaak tot een zoektocht naar 
biomarkers die niet afhankelijk zijn van spiermassa om de nierfunctie accuraat 
te weerspiegelen in de oudere populatie. 
  In hoofdstuk 4.1 werd de aandacht verschoven van nierfunctie en 
fysieke gezondheid naar nierfunctie en mentale gezondheid, een andere 
belangrijke uitkomt op oudere leeftijd. De baseline data van de SCOPE studie 
werd onderzocht op mogelijke verbanden tussen nierfunctie, geheugen en 
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stemming. Achteruitgang van al deze functies kan worden veroorzaakt door 
vasculaire mechanismen zoals aantasting van de microcirculatie van goed 
gevasculariseerde organen waaronder de nieren en het brein. Onze resultaten 
bevestigen die hypothese verassend genoeg niet; cognitieve stoornissen 
en depressieve symptomen kwamen niet vaker voor bij ouderen met 
nierfunctiestoornissen en, vice versa, ouderen met cognitieve stoornissen 
en depressieve symptomen hadden vergelijkbare geschatte nierfuncties met 
ouderen zonder problemen met de cognitie en stemming. Echter, omdat 
ook hier gebruik werd gemaakt van een geschatte nierfunctie gebaseerd op 
kreatinine, zou de hypothese idealiter nogmaals getoetst moeten worden met 
een methode die accurater de nierfunctie weerspiegelt. 
  Deel II van het proefschrift dat de hoofdstukken 5 en 6 beslaat, richt 
zich op vasculaire veroudering. 
  Hoofdstuk 5 bestaat uit drie delen waarin de mogelijke gevolgen 
van vaatverstijving worden beschreven met aandacht voor diverse (orgaan)
systemen en algehele kwaliteit van het late leven.
  Hoofdstuk 5.1 beschrijft mogelijke links tussen enerzijds vaatstijfheid 
en anderzijds botontkalking en spierverlies in een narratieve review. Een 
groot aantal klinische studies vonden een verband en deze verbanden bleken 
grotendeels onafhankelijk van leeftijd en andere (potentiële) risicofactoren. 
Echter, op basis van bekende literatuur kwam naar voren dat het niet geheel 
duidelijk is hoe deze processen, die leeftijdsgerelateerd zijn, op elkaar 
inwerken. Mogelijke hypothesen die wij beschrijven zijn onder andere de rol 
van het immuunsysteem, hormonale veranderingen en een veranderd glucose 
metabolisme. Deze factoren versnellen mogelijk het proces van vasculaire 
veroudering en botmassa- en spierverlies. Omdat er slechts beperkte 
longitudinale studies verricht zijn, kan er niet tot nauwelijks een causaal 
verband worden onderzocht. Het diepgaande overzicht van de mogelijke 
hypotheses die aan deze associaties ten grondslag liggen, suggereert echter 
dat interventies gericht op de onderliggende factoren zouden kunnen helpen 
om deze processen te vertragen en bijkomende complicaties te voorkomen. 
  In het onderzoek in hoofdstuk 5.2 bestudeerden wij de associatie 
tussen indicatoren van vaatstijfheid en kwaliteit van leven. Wij vonden dat 
ouderen met een sub-optimale kwaliteit van leven hogere vaatstijfheid 
hadden dan ouderen met een optimale kwaliteit van leven onafhankelijk van 
leeftijd en comorbiditeit. Deze resultaten suggereren dat vaatstijfheid gezien 
kan worden als een subklinische biomarker van vitaliteit in het late leven 
waarschijnlijk als gevolg van een negatieve invloed op fysiek en geestelijk 
functioneren. 
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  Het onderzoek in hoofdstuk 5.3 beschrijft mogelijke associaties 
tussen vaatstijfheid, grijze stof volume en volume van witte stof schade in 
het brein. Een hogere vaatstijfheid was geassocieerd met een lager grijze 
stof volume en een hogere mate aan witte stof schade. Deze associatie 
was onafhankelijk van bloeddruk, maar werd sterk gemedieerd door leeftijd. 
Leeftijd kan waarschijnlijk worden gezien als de belangrijkste speler in 
vaatverstijving die tevens negatieve veranderingen teweegbrengt in de 
integriteit van het brein. 
  Of ook de veranderde bloeddruk profielen een effect hebben 
op het late leven wordt beschreven in hoofdstuk 6.1. Wij vonden dat 
diastolische bloeddruk veranderingen bij het opstaan een hoger risico gaven 
op het hebben van angst om te vallen: hoe groter de daling in diastolische 
bloeddruk, hoe groter het risico op angst om te vallen. Deze associatie werd 
niet gevonden tussen systolische bloeddruk veranderingen en angst om te 
vallen. Dit suggereert dat de verstoring van diastolische bloeddruk regulatie 
hoogst waarschijnlijk belangrijke implicaties heeft in het late leven en het 
beter reguleren van de diastolische bloeddruk zou dus een belangrijk doel 
kunnen zijn voor behoud van kwaliteit van leven op oudere leeftijd. 
  Tot slot bevat hoofdstuk 7 een algemene discussie over de 
onderzoeken die in dit proefschift zijn beschreven. Dit proefschrift geeft 
inzicht in onderliggende patronen die mogelijk betrokken zijn bij het 
(versnelde) verouderingsproces in een poging nieuwe doelwitten aan het licht 
te kunnen brengen voor betere diagnostische en therapeutische strategieën 
en daarmee kwaliteit in het late leven te behouden of zelfs te verbeteren. 
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